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Abstract 
 
This study examines three process measures of diabetic care and their association with four 
complications of diabetes - Coronary Artery Disease (CAD), Heart Failure (HF), Stroke and 
Renal Disease (RD) - in a cohort comprised of hourly and salaried employees of a single large 
manufacturing company at geographically diverse regions in the United States. Quality of care 
was measured by adherence to consensus standards for A1C and lipid testing and screening for 
microalbuminuria. A retrospective cohort study was conducted from January 1, 2003 to 
December 31, 2009 of 1,797 diabetic employees of a US manufacturer who were enrolled in the 
same health insurance plan.  Diabetics who received all three QOCM in the baseline year were 
compared to diabetics who received less than three QOCM in the baseline year and were 
analyzed to address their association with the four complications.  
Cox proportional hazard regression models were used to assess potential associations 
between diabetes QOCM and time to complication.  Potential confounding risk factors included 
sex, age, ethnicity, income, marital status, education, smoking, diabetes severity and health 
comorbidity risk scores.   
The overall health benefits for diabetics who received all three QOCM at baseline were 
noteworthy; they experienced reduced risk for HF (HR 0.39, CI [.19 - .81], p = 0.0117) and RD 
v 
 
(HR 0.48, CI [.24 - .95] p = 0.0339) compared to the people who received less than three 
QOCM.  Results suggest that diabetics who  received all  three QOCM  experienced  lower 
complications and is associated with reduced complication risk - regardless of access to care and 
other factors.  These results suggest that any improvement in screening is likely to reduce the 
risk of diabetes complications.  This study contributes to the literature by examining adherence 
to recommended processes of care and patient complications together.  The public health 
implications of this study can be used to inform the design or revision of disease management 
programs and process of care measures. 
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1.0  INTRODUCTION 
Diabetes presents a significant public health burden that leads to increased morbidity, mortality, 
and economic costs (Saydah, Fradkin, & Cowie, 2004).  In 2010, the estimated prevalence of 
diabetes among persons aged 18 years or older ranged from five to 13% in the United States and 
its territories (Chowdhury et al., 2010).  Diabetes can cause debilitating physical complications, 
including cardiovascular disease (Centers for Disease Control and Prevention, 2010; Grundy et 
al., 1999; Haffner, Lehto, Rönnemaa, Pyörälä, & Laakso, 1998), heart failure (Boudina & Abel, 
2007), stroke (Feskens & Kromhout, 1992; Herlitz, Karlson, Lindqvist, & Sjolin, 1998; Kissela 
et al., 2005; Kuusisto, Mykkanen, Pyorala, & Laakso, 1994; Rodbard et al., 2007), renal disease 
(Gross et al., 2005; Levin & Rocco, 2007; Perneger, Brancati, Whelton, & Klag, 1994), 
hypertension (Rodbard et al., 2007; Sowers, Epstein, & Frohlich, 2001) and visual impairment 
(Klein, Klein, Moss, Davis, & DeMets, 1984; Singh, Armstrong, & Lipsky, 2005; Zhang et al., 
2006), among others.  Diabetes often develops nine to 12 years before it is diagnosed (Lillioja et 
al., 1993). More than 50% of patients diagnosed with T2DM have at least one complication at 
the time of diagnosis that could have been prevented (Rodbard et al., 2007). 
 On average, medical expenditures for people with diagnosed diabetes are more than 
double those of the non-diabetic population.  Approximately one out of every five health care 
dollars in the US is spent caring for someone with diagnosed diabetes, which in 2007 totaled 
$174 billion, including $116 billion in excess medical expenditures and $58 billion in reduced 
 2 
national productivity (Petersen, 2008).  An additional $58 billion was spent that same year 
treating microvascular and macrovascular complications of diabetes, including myocardial 
infarction, stroke, renal disease, retinopathy and neuropathy, along with $31 billon in excess 
general medical costs (Petersen, 2008).   
 In addition to medical complications and the related physical and financial burdens they 
cause, diabetes impacts lives in many other ways.  Approximately 11 to 15% of patients with 
Type 2 diabetes (T2DM) also suffer from major depression (Katon et al., 2005).  Diabetes also 
has a financial cost in the form of increased absenteeism ($2.6 billion), reduced work 
productivity for the employed population ($20.0 billion), reduced productivity for those not in 
the labor force ($0.8 billion), unemployment due to disease-related disability ($7.9 billion), and 
lost productive capacity due to early mortality ($26.9 billion).  Compared to individuals without 
diabetes, men and women with diabetes are 5.4% and 6% more likely to have work limitations, 
respectively.  Diabetes affects patients, employers, and society at large, not only by reducing 
employment but also by contributing to work loss and health-related work limitations for those 
who remain employed (Petersen, 2008; Tunceli et al., 2005). 
 Fortunately, a significant body of research from large randomized controlled trials has 
clearly established that several effective treatments and practices provide evidence that intensive 
treatment of diabetes mellitus and conditions known to be risk factors can significantly decrease 
the development and/or progression of chronic complications (DCCT, 1993, 1996; EDIC, 1999; 
ETDRS, 1991; Goldberg et al., 1998; Knowler et al., 2002; Litzelman et al., 1993; Mann, 2000; 
Ohkubo et al., 1995; Rodbard et al., 2007; Stratton et al., 2000; UKPDS 33, 1998; UKPDS 38, 
1998; UKPDS 40, 1998).  Specific benefits are derived by monitoring and controlling glycemia, 
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blood pressure and lipids, screening for microalbuminuria and retinopathy, and conducting 
routine foot examinations (Saaddine et al., 2006).   
 For most of the 20th century, diabetes care was suboptimal and varied in the United 
States (Beckles et al., 1998; Engelgau et al., 1998; Fleming et al., 2001; Kenny, Smith, 
Goldschmid, Newman, & Herman, 1993; Saaddine et al., 2006).  It was recognized that a 
national consensus on process measures could enhance the delivery of care and provide a method 
for assessing care within and across health care settings while providing a meaningful 
mechanism for quality improvement.  Founded in 1997, the National Diabetes Quality 
Improvement Project developed a comprehensive set of process and intermediate outcome 
measures to assess quality of care for diabetes patients that are now considered standard 
(Fleming et al., 2001).  The measures were developed based on the theory that if diabetics and 
their physicians adhere to the process and intermediate outcome measures they will have fewer 
complications (Fleming et al., 2001).  The process measures include annual screenings for lipids 
and microalbuminuria and at least two measurements of A1C ( a measure of blood glucose levels 
over the preceding three months), as well as annual flu vaccinations, dilated eye exams and 
biannual foot examinations (American Diabetes Association, 2005).  The American Diabetes 
Association Provider Recognition Program, the American Medical Association Diabetes 
Measures Group, the Veterans Administration’s performance monitoring program, the National 
Committee for Quality Assurance (NCQA) and other national consensus standards and the 
Health Plan Employer Data and Information Set (HEDIS) include these process measures as part 
of their performance monitoring programs.   
A number of studies (Beckles et al., 1998; Fleming et al., 2001; Grant, Buse, & Meigs, 
2005; Imperatore et al., 2004; Jencks, Huff, & Cuerdon, 2003; Kenny et al., 1993; Koro, Bowlin, 
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Bourgeois, & Fedder, 2004; Mangione et al., 2006; McClain, Wennberg, Sherwin, Steinmann, & 
Rice, 2003; Rodbard et al., 2007; Roubideaux et al., 2004; Saaddine et al., 2006; Saaddine et al., 
2002; Sawin, Walder, Bross, & Pogach, 2004; Saydah et al., 2004; Selby et al., 2007) have used 
these performance measures to assess and document improvement in the care provided to 
patients with diabetes at the health system, provider and health plan levels.  These studies 
provide evidence of the substantial gaps between national performance measures for diabetes 
care (e.g., frequent A1C testing, screenings for diabetic retinopathy, cholesterol testing, routine 
foot exams, etc.) and actual care received by diabetics in the United States.  For instance, using 
three performance indicators from the NCQA and HEDIS  guidelines, one research study (Jencks 
et al., 2003) found that the percentage of Medicare patients receiving appropriate diabetes related 
preventative care services in 1998 and 1999 in the median state was just 71% for A1C, 69% for 
eye exams and 57% for cholesterol testing.  A follow up study of the same cohort in 2000 and 
2001 indicated that care had improved substantially for the same medical conditions to 78%, 
70%, and 74%, respectively (Jencks et al., 2003). 
 Optimal diabetes care depends on healthcare providers adhering to evidence-based 
practice guidelines in the delivery of care, and patients adhering to self-management 
recommendations in order to maximize intermediate outcomes and reduce complications (Ward 
et al., 2004).   Process measures assess the degree to which providers follow the evidence-based 
practice guidelines (e.g., the percentage of patients with two A1C tests in a year, at least one 
lipid test in a year, at least one screen for microalbuminuria in a year, etc.).  Intermediate 
outcome measures assess the extent of glycemic, lipid, and blood pressure control in patients 
with diabetes (e.g., the percentage of patients with a measured A1C < 7% and a measured low-
risk lipid cholesterol (LDL) value ≤ 100 mg/dl).  Process and outcome measures are distinct and 
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complementary aspects assessing quality of diabetes care, and the relationship between processes 
of care and patient outcomes, specifically, complications, are a central issue in health services 
research.    
Although it has not been firmly established that early detection of T2DM and 
intervention actually improves long-term outcomes, several studies provide evidence that 
adherence to consensus standards is associated with reduced complications.  The results of both 
UKPDS studies and the DCCT are consistent: intensive glycemic monitoring and control 
significantly reduces microvascular complications (DCCT, 1993, 1996; DCCT/EDIC, 2000; 
Duckworth et al., 2009; Margetts, 1995; Nathan et al., 2005; Nathan et al., 2009; Phillips & 
Molitch, 1995; UKPDS 33, 1998).  Other meta analyses also have demonstrated a reduction in 
the risk of heart disease with intensive decreases in blood glucose versus standard treatment 
(Kelly et al., 2009; Klein, 1995; Nathan et al., 2005; Ray et al., 2009; Stratton et al., 2000).    
Additionally, achieving high metabolic control (A1C  <  7%), treating hypertension (< 130/80 
mm Hg or < 125/75 mm Hg if proteinuria > 1.0 g/24 h and increased serum creatinine), using 
drugs with blockade effects on the renin-angiotensin-aldosterone system, and treating 
dyslipidemia (LDL cholesterol < 100 mg/dl) are effective in preventing the development of 
microalbuminuria, delaying the progression to more advanced stages of nephropathy, and 
reducing cardiovascular mortality in patients with T1DM and T2DM (Gross et al., 2005; Levin 
& Rocco, 2007).  The results of multiple large randomized controlled trials also indicate that 
blood pressure control reduces morbidity and mortality among diabetics (Adler et al., 2000; 
Gross et al., 2005; Newman et al., 2005; Saydah et al., 2004; UKPDS 33, 1998; UKPDS 38, 
1998).  Proper screening (e.g., dilated fundus examination), glycemic and hypertension control, 
and early interventions incorporating both surgical and pharmacologic therapies also can help 
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diabetics avoid severe vision loss associated with diabetic retinopathy (Mohamed, Gillies, & 
Wong, 2007).  
 Computer simulation models of T2DM of subjects over age 25 suggest that the cost 
increases associated with screening and early treatment may be worth it (Engelgau et al., 1998).   
However, it is important to note that the benefits of early detection in the model were derived 
more from postponement of complications from diabetes than from additional life-years.  In 
other analyses, screening for impaired glucose tolerance and undiagnosed T2DM followed by 
intervention was more cost effective than no screening at all (Gillies et al., 2008). 
1.1 ACCESS TO CARE AND SES 
 It is unknown whether improvements in adherence to national consensus standards for 
diabetes have benefited all groups equally, or whether, as noted in earlier studies (Karter et al., 
2002), socioeconomic differences that lead to substandard health care for minorities remain.  The 
availability of health insurance is a strong factor associated with better process and outcome 
measures (Saaddine et al., 2002).  However, reasonable access to health care depends on many 
factors, including the availability of health services in a community and personal care-seeking 
behavior.  These and other factors are often trumped by whether a person can afford the costs of 
needed care. Health services research shows a strong association between health insurance 
coverage and access to primary and preventive care, the treatment of acute and traumatic 
conditions, and the medical management of chronic illnesses such as diabetes (Hoffman & 
Paradise, 2008).  The same research connects being uninsured or underinsured with adverse 
health outcomes, including declines in health and functioning, the existence of preventable health 
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problems, severe disease at the time of diagnosis, and premature mortality (Hoffman & Paradise, 
2008; Institute of Medicine, 2002).  Although health insurance alone would neither eliminate 
disparities in access to health care nor equalize health across subgroups of Americans, having 
health insurance is clearly connected to a longer life of better quality (Institute of Medicine, 
2002).   
 Disparate access to quality health care is a common explanation for socioeconomic and 
ethnic disparities in diabetic complication rates within the US population (Selby et al., 2007; 
Smedley, Stith, & Nelson, 2002).  Population-based studies suggest that racial and ethnic 
minorities and people of lower socioeconomic status (SES) experience worse long term diabetes 
outcomes  than whites and people of higher SES (Brown et al., 2005).  Other studies have shown 
less adherence to processes of diabetes care (dilated retinopathy, etc.) and worse intermediate 
outcomes among racial and ethnic minorities and individuals with lower incomes or education 
levels (Karter et al., 2002; Lanting, Joung, Mackenbach, Lamberts, & Bootsma, 2005).  Since 
racial and ethnic minorities and poorer people with diabetes are less adequately insured than 
whites or people higher on the SES ladder (Brown et al., 2005), differential access to care may 
contribute to these observations.  Research from managed care settings (Karter et al., 2002; 
Martin, Selby, & Zhang, 1995) and the Veterans Health Administration (Heisler, Smith, 
Hayward, Krein, & Kerr, 2003; Young, Maynard, & Boyko, 2003) suggest that racial and ethnic 
disparities in diabetes processes and outcomes may be reduced in settings offering more uniform 
access to care.  In the TRIAD research, 7,456 adults who were enrolled in health plans 
participated in a six center cohort study on diabetes treatment and outcomes in a managed care 
setting; minority race and ethnicity were consistently associated with worse processes or 
outcomes (Brown et al., 2005).  Access to care and associated variables such as SES and 
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ethnicity are frequent confounders in research studies examining the relationship between quality 
of diabetes care and intermediate outcomes and complications using participant samples from the 
general population. 
1.2 RESEARCH JUSTIFICATION 
Changing demographics in the US population will only fuel the diabetes epidemic, and many 
more people will be stricken with the disease in the years to come (Centers for Disease Control 
and Prevention, 2008).  Ensuring access to and delivery of high-quality care for all people with 
diabetes should be a national priority, as it has serious financial and social implications.  
Understanding how to better implement existing diabetes care interventions with minimal 
resources will be critical to ensuring the highest possible quality of life for millions of Americans 
afflicted with the disease.  
Healthy People 2010, a document created by the US Department of Health and Human 
Services, highlights wide gaps between public health performance and actual outcomes based on 
many quality indicators (Jencks et al., 2003; US Department of Health and Human Services, 
2010).  Despite advances in diabetes research and consensus recommendations for diabetes care, 
adherence to patient care processes and health outcomes are still falling short of targeted levels 
(Saaddine et al., 2006; Saaddine et al., 2002). Furthermore, even people with apparently good 
access to health services receive care that falls far short of what it could be (Jencks et al., 2003).  
As previously stated, there is data suggesting a relationship between health outcomes in diabetics  
and quality of care received  (Saaddine et al., 2002, (Hoffman & Paradise, 2008;  Brown et al., 
2005; Martin, Selby, & Zhang, 1995) However these results are confounded by factors such as  
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social and access differences between groups. Therefore, it is not entirely clear if the quality of 
care received is the primary factor that improves the outcome in diabetics or the good 
socioeconomic circumstances such as income, education, ethnicity and other social factors that 
allows good care to occur. 
 
This study examines three process measures of diabetic care and their association with 
four complications of diabetes - Coronary Artery Disease (CAD), Heart Failure (HF), Stroke and 
Renal Disease (RD) - in a cohort comprised of hourly and salaried employees of a single large 
manufacturing company at geographically diverse regions in the United States. This cohort 
provides a unique opportunity to answer the study question because of the ethnic diversity of the 
population, the uniform health care benefits offered by the employer and the comparable access 
to healthcare by the workers.  Processes of care will be measured by adherence to consensus 
standards for A1C and lipid testing and screening for microalbuminuria. Most of the diabetes 
care literature focuses on adherence to patient care processes (e.g., frequency of A1C testing, 
lipid testing, vision screening, etc.) and intermediate outcomes such as the actual levels of A1C 
testing, results of lipid tests and actual blood measurements.; very few evaluate adherence and 
actual outcomes and complications (Renders et al., 2001).  Because of the unique database and 
the study design, actual outcomes of diabetic complications (CAD, HF, Stroke and RD), and not 
intermediate outcomes of care will be evaluated in this analysis. This is important because of the 
ability of this study to separate out the care processes from other explanations of why the people 
who got good care did better. 
The employer’s electronic administrative data for personnel, financial and health 
insurance will be used to obtain sex, age, ethnicity, income and marital status minimizing the 
potential confounding associated with SES covariates.  The study setting will reduce the 
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potential for random effects by evaluating the quality of care delivered through the same 
provider networks within the employment context and minimize confounding associated with 
access to care.  Studying a geographically and ethnically diverse population of diabetics 
employed by a US manufacturer with the same insurance is a  highly advantageous study setting 
for analyzing associations of quality of healthcare and disease outcomes (Einav, Finkelstein, & 
Cullen, 2010; Einav, Finkelstein, Pascu, & Cullen, Under Review; Einav, Finkelstein, Ryan, 
Schrimpf, & Cullen).  
Measuring quality of care processes and complications in isolation yields incomplete 
results and ignores important implications for diabetes care; the two should not be separated.  
This study contributes to the literature by examining adherence to recommended processes of 
care and patient complications together and by providing insights into why some diabetics are 
not yet benefiting fully from quality improvement efforts (Jencks et al., 2003; US Department of 
Health and Human Services, 2010).  In this way, the results of this study can be used to inform 
the design or revision of disease management programs and process of care measures. 
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2.0  LITERATURE REVIEW 
2.1 PREVALENCE OF DIABETES  
In 2008, the Centers for Disease Control and Prevention (CDC) reported that 1.6 million 
Americans aged 20 years or older are diagnosed with diabetes each year (Centers for Disease 
Control and Prevention, 2008).  Currently, diabetes is the seventh leading cause of death, 
affecting nearly 24 million people in the United States (Centers for Disease Control and 
Prevention, 2008, 2011).  “As the worldwide diabetes epidemic continues to unfold, some 
experts have asked whether the war against it is being lost” (Fleming et al., 2001).   
Based on a CDC analysis of the National Health Interview Survey, the number of adults 
in the United States with diagnosed diabetes has increased by 61% since 1991, and is projected 
to more than double by 2050 (Centers for Disease Control and Prevention, 2011). The CDC 
report predicts that the number of new diabetes cases each year will increase from 8 per 1,000 
people in 2008, to 15 per 1,000 in 2050.  These projected increases are largely attributable to the 
aging US population, an increasing number of people from higher risk ethnic origins, and the 
fact that people with diabetes are living longer (Boyle et al., 2001).  If current trends continue, 
those with diabetes will lose an average of 10 to 15 life-years (Narayan, Boyle, Thompson, 
Sorensen, & Williamson, 2003; Saaddine et al., 2006).  Similarly, if diabetes mortality rates 
remain relatively low, diabetes prevalence in the United States will increase to 33% by 2050 
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(Centers for Disease Control and Prevention, 2010).  Therefore, effective strategies must be 
created to buffer the financial and societal impact of diabetes on the nation.  
Given the large number of Americans with undiagnosed diabetes mellitus, early detection 
and treatment is imperative to addressing the diabetes epidemic (Centers for Disease Control and 
Prevention, 2011; Rodbard et al., 2007).  In 1997, the Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus issued new diagnostic and classification criteria (Gavin et al., 
1997), and in 2003, modifications were made regarding the diagnosis of impaired fasting glucose 
(Genuth et al., 2003).  Today, diabetes is classified into four clinical types:  
1.  Type 1 diabetes mellitus (T1DM), resulting from cell destruction and usually leading 
to absolute insulin deficiency;  
2.  Type 2 diabetes mellitus (T2DM), resulting from a progressive insulin secretion defect 
coupled with insulin resistance;   
3.  Gestational diabetes mellitus, diagnosed in women during pregnancy; and 
4.   Specific types of diabetes due to other causes (e.g., genetic defects in cell function, 
genetic defects in insulin action, diseases of the pancreas, and induced by drugs or 
chemicals) (American Diabetes Association, 2005, 2010). 
Approximately 90 to 95% of all diabetes diagnoses in the United States are T2DM 
(Rodbard et al., 2007), and the disease often develops nine to 12 years before it is diagnosed 
(Lillioja et al., 1993).  T2DM is caused by a combination of complex metabolic disorders that 
result from coexisting defects of multiple organs, including insulin resistance in muscle and 
adipose tissue, a progressive decline in pancreatic insulin secretion, unrestrained hepatic glucose 
production and other hormonal deficiencies (Aronoff, Berkowitz, Shreiner, & Want, 2004; 
Ferrannini, 1998; Lillioja et al., 1993).  T2DM occurs more frequently in women with a history 
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of gestational diabetes and in individuals with hypertension or dyslipidemia.  Diabetes is also 
associated with a strong genetic predisposition. Almost all other cases (five to 10%) are T1DM, 
with gestational diabetes or diabetes from other causes accounting for just a fraction of diagnoses 
(Rodbard et al., 2007).  Some patients cannot be clearly classified as having T1DM or T2DM 
even though the clinical presentations and disease progressions vary considerably (American 
Diabetes Association, 2010; Rodbard et al., 2007).  In many cases, the true diagnosis may 
emerge only over time. 
2.2 DIABETES COMPLICATIONS  
Diabetes is associated with a high prevalence of comorbidities (Katon et al., 2005).  Several risk 
factors, including obesity, a sedentary lifestyle, genetic predisposition, ethnicity and advanced 
age increase the risk of developing diabetes; when coupled with conditions such as hypertension 
and dyslipidemia, they exacerbate the potential for related macrovascular and microvascular 
complications (Adler et al., 2000; Bakris et al., 2000; Coutinho, Gerstein, Wang, & Yusuf, 1999; 
Fong et al., 2004; Fox, Sullivan, D’Agostino, & Wilson, 2004; Frank, 2004; Gerstein et al., 
2007; Gross et al., 2005; Haffner, Lehto, Rönnemaa, Pyörälä, & Laakso, 1998; Khaw et al., 
2001; Klein, Barrett-Connor, Blunt, & Wingard, 1991; Miettinen et al., 1998; Perneger, Brancati, 
Whelton, & Klag, 1994; Phillips & Molitch, 1995; Ray et al., 2009; Rodbard et al., 2007; Selvin 
et al., 2004; Stratton et al., 2000; Tuomilehto, 2003; UKPDS 33, 1998; UKPDS 38, 1998; Vinik, 
Maser, Mitchell, & Freeman, 2003).  Macrovascular complications include:  coronary artery 
disease, which can lead to myocardial infarction; cerebral vascular disease, which can lead to 
strokes; and peripheral vascular disease.   Microvascular complications include nephropathy or 
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renal disease (disease of the kidney), which can require dialysis and lead to kidney failure; 
retinopathy (disease of the retina), which can lead to blindness; and neuropathy (disease of the 
nerves), which can lead to foot ulcerations and amputation (Lillioja et al., 1993).    
 Many of these complications produce no symptoms in the early stages, and more than 
50% of patients diagnosed with T2DM have at least one complication at the time of diagnosis 
that could have been prevented (Rodbard et al., 2007).  Approximately 20% of newly diagnosed 
T2DM patients have diabetic retinopathy (Harris, Klein, Welborn, & Knuiman, 1992), 10% have 
nephropathy (Klein, Klein, Moss, & DeMets, 1988), and almost all have already lost 50% of beta 
cell function (Harris et al., 1992).   
Although diabetes is associated with many complications, this review will focus on the 
four complications assessed in this study:  CAD, HF, stroke and RD. A brief overview of other 
complications (i.e., hypertension, diabetic retinopathy and diabetic neuropathy) is included at the 
end of the chapter.  Although they are beyond the scope of this study, these complications often 
develop along with CAD, HF, stroke and RD and thus are covered for informational purposes. 
2.2.1 Coronary artery disease (CAD) 
Cardiovascular disease is the main cause of morbidity and mortality in diabetic patients (Centers 
for Disease Control and Prevention, 2010; Grundy et al., 1999; Haffner et al., 1998). Results 
from epidemiologic studies show that hyperglycemia is strongly associated with the development 
of cardiovascular disease (Coutinho et al., 1999; Khaw et al., 2001; Tuomilehto, 2003).  
Compared to individuals without diabetes, those with diabetes have a higher prevalence of CAD 
and coronary ischemia, and are more likely to have myocardial infarctions (MI) and silent 
myocardial ischemia (Rodbard et al., 2007).  The risk of CAD is directly related to the duration 
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of diabetes (Fox, Sullivan et al., 2004; Miettinen et al., 1998).   The US National Cholesterol 
Education Program (NCEP) report considers T2DM to be a CAD equivalent that increases the 
occurrence and accelerates the progression of coronary events, strokes, and peripheral arterial 
disease, placing it in the highest risk category (Antonopoulos, 2002).  This classification was 
based in part upon the observation that patients with T2DM without a history of MI, and patients 
without diabetes with a history of MI, were at almost the same risk for future MI (20 and 19%, 
respectively) and coronary mortality (15 and 16%, respectively) (Haffner et al., 1998). Similar 
findings have been noted in other studies (Libby et al., 2005).  Compared to individuals without 
diabetes, the long and short-term prognoses following a coronary event are worse for diabetes 
patients, especially women (Hu et al., 2001); the rates for reinfarction, congestive heart failure, 
and death are increased, and revascularization procedures are less successful (Miettinen et al., 
1998).  In addition, CAD, when coupled with hypertension, hyperglycemia and elevated lipids, 
puts diabetics at increased risk not only for myocardial infarction, but also for renal disease 
(Bakris et al., 2000).  
The Framingham Heart Study was the first to report the importance of the association 
between diabetes and heart disease (Kannel & McGee, 1979b).  In the study, the presence of 
diabetes doubled the age-adjusted risk for cardiovascular disease in men and tripled it in women 
(Kannel & McGee, 1979b).  Diabetes remained a major independent cardiovascular risk factor 
even when adjusting for increasing age, hypertension, smoking, dyslipidemia, and left 
ventricular hypertrophy (Kannel & McGee, 1979b).  
Most studies of diabetes and CAD compare T2DM diabetics to non-diabetics.  In a 
review of 292 patients with T1DM, heart disease-related mortality increased rapidly after the age 
of 30, particularly in patients with renal disease (Krolewski et al., 1987).  The cumulative CAD 
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mortality was 35% by age 55, compared to eight and four percent in non-diabetic men and 
women, respectively, in the Framingham Heart Study (Kannel & McGee, 1979a).  Similar 
relationships were noted for nonfatal MI and angina.  When compared to non-diabetics of similar 
age, the risk for cardiovascular disease in patients with T1DM is even greater than for patients 
with T2DM (Krolewski et al., 1987). 
Even though the incidence of CAD has declined substantially in all adults over the last 
several decades, diabetic patients are still at greater risk (Fox, Coady et al., 2004).  CVD 
incidence rates were calculated for diabetic and non-diabetic participants aged 45 to 64 years in 
the Framingham Heart Study, which examined an original cohort between 1950 and 1966 (4,118 
participants, 113 with diabetes) and an offspring cohort between 1977 and 1995 (4,063 
participants, 317 with diabetes).  The CVD incidence rates were compared between the original 
and offspring cohorts based on main outcome measures of MI, coronary heart disease death, and 
stroke.  Among participants with diabetes, the age- and sex-adjusted CVD incidence rate was 
286.4 per 10,000 person-years in the earlier period and 146.9 per 10,000 person-years in the later 
period, a 49.3% (95% CI [16.7% - 69.4%]) decline (Fox, Coady et al., 2004).  Among 
participants without diabetes, the age- and sex-adjusted incidence rate was 84.6 per 10,000 
person-years in the earlier period and 54.3 per 10,000 person-years in the later period, a 35.4% 
(95% CI [25.3% - 45.4%]) decline (Fox, Coady et al., 2004).  Although the age- and sex-adjusted 
rates for cardiovascular events declined, diabetes was still associated with a two-fold increase in 
risk (multivariate-adjusted HR 1.96, 95% CI [1.44 - 2.66]) (Fox, Coady et al., 2004). 
The role of insulin as a cardiovascular risk factor in T2DM remains controversial.  
Several prospective studies have investigated the association between insulin therapy and CAD 
with contradictory results. The U.K. Prospective Diabetes Study (UKPDS) did not find an 
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association between treatment with insulin and macrovascular outcomes among newly diagnosed 
diabetic subjects (UKPDS 38, 1998).  However, the Feasibility Trial of the Veterans Affairs 
Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM) initially found a significant increase 
in cardiovascular events among older veterans with established T2DM who received intensive 
insulin treatment (Abraira et al., 1997).  In a follow-up study, the VA CSDM study group 
reported that intensive insulin treatment did not affect left ventricular function (Pitale et al., 
2000).   
2.2.2 Heart failure (HF) 
Diabetes mellitus is a well-recognized risk factor for developing heart failure (HF) (Boudina & 
Abel, 2007).  The Framingham Heart Study showed that HF occurs twice as often in diabetic 
men and five times as often in diabetic women compared with age-matched control subjects 
(Kannel & McGee, 1979a).  In a study of 9,591 patients with T2DM and matched controls, HF 
was more prevalent at baseline in diabetic subjects (11.8%, n = 1,131) than in control subjects 
(4.5%, n = 435) (Nichols, Hillier, Erbey, & Brown, 2001).  The slopes of the increasing 
prevalence and incidence of HF across age groups were very similar for subjects with and 
without diabetes.  This suggests that diabetes adds a more or less constant risk of HF, 
independent of age.   Nichols and colleagues (2001) found that the prevalence of HF doubled 
with each decade of age, confirming an observation reported in the Framingham Heart Study 
(Kannel & McGee, 1979a).   
HF patients with diabetes have poorer survival rates than those who do not have diabetes.  
In a national sample of Medicare claims of 151,738 beneficiaries, HF was prevalent in 22.3% of 
the sample in 1994.  Among individuals without HF in 1994, the incidence rate for HF over the 
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five-year study was 12.6 per 100 person-years (95% CI [12.5-12.7 per 100 person-years]) 
(Bertoni et al., 2004).  Incidence was similar by sex and race and increased significantly with age 
and diabetes-related comorbidities. The adjusted hazard rate for HF increased for individuals 
with the following: metabolic complications of diabetes (a proxy for poor control and/or 
severity) (HR 1.23, 95% CI [1.18 - 1.29]), ischemic heart disease (1.74, 95% CI [1.70 - 1.79]), 
nephropathy (1.55, 95% CI [1.45 - 1.67]), and peripheral vascular disease (1.35, 95% CI [1.31 - 
1.39]) (Bertoni et al., 2004).  Over 60 months, HF among older adults with diabetes was 
associated with high mortality, 32.7 per 100 person-years, compared with 3.7 per 100 person-
years among those with diabetes who did not develop HF (Bertoni et al., 2004).  These data 
demonstrate a high prevalence, incidence, and mortality for HF in individuals with diabetes.   
 
2.2.3 Stroke       
Stroke is a preventable disease that significantly impacts quality of life and is associated with a 
high cost to society.  Preventing stroke in people with diabetes is feasible through identifying and 
treating risk factors, especially hypertension, cigarette smoking, and dyslipidemia (Air & 
Kissela, 2007; Kuller, 1995; Rodbard et al., 2007).  The incidence and prevalence of stoke 
among diabetics may be higher now than was suggested in the past due to improved clinical 
diagnosis through computerized tomography (CT) and magnetic resonance imaging (MRI) 
(Kuller, 1995).  These diagnostic tools identify “silent” strokes and are also used more frequently 
among older individuals who receive frequent medical care (Kuller, 1995).  Given the high 
prevalence of undetected diabetes in the US population (Centers for Disease Control and 
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Prevention, 2008, 2011; Rodbard et al., 2007) and the fact that incidence of stroke increases with 
advanced age, many stroke patients may, in fact, have undetected diabetes when strokes occur.   
While significant progress has been made in understanding the link between diabetes and 
CAD, the scientific literature on diabetes and stroke is less robust.  Individuals with T2DM have 
strokes three times more often than non-diabetics in the general population (Feskens & 
Kromhout, 1992; Herlitz, Karlson, Lindqvist, & Sjolin, 1998; Kuusisto, Mykkanen, Pyorala, & 
Laakso, 1994; Rodbard et al., 2007).  The results of multiple large randomized controlled trials 
indicate that blood pressure control reduces morbidity and mortality among patients who have 
had strokes (Rodbard et al., 2007).  Controlling hypertension is critical in preventing stroke, 
myocardial infarction, and renal failure in diabetics.   
The relationship between diabetes and stroke has been substantiated in various studies of 
racial and ethnic groups (Kissela et al., 2005) women, and older individuals (Air & Kissela, 
2007; Sowers, 2003).  The greater Cincinnati/Northern Kentucky Stroke Study (GCNKSS), a 
population-based study of 2,719 African American and white ischemic stroke patients used data 
extracted from hospital discharge codes and emergency room logs, coroner’s cases and sampling 
in non-hospital settings (Kissela et al., 2005).  African Americans in the study cohort were more 
likely to have diabetes (36%) than whites (30%, p = 0.005).  In addition, ischemic stroke patients 
with diabetes were younger (< 55 years old for African Americans, < 65 years old for whites) 
than the ischemic stroke patients without diabetes.  They were also less likely to be current 
smokers at the time of their strokes and more likely to have been previously diagnosed with 
hypertension, high cholesterol, and MI.  For African Americans, a medical history of diabetes or 
both diabetes and hypertension was significantly associated with increased risk of stroke (OR 
2.7, 95% CI [1.5 - 5.2], OR 3.0, 95% CI [2.1 - 4.3] respectively).  Among African Americans, 
 20 
diabetic stroke patients did not have higher rates of elevated cholesterol, MI, or atrial fibrillation 
compared to their non-diabetic counterparts, but they did have higher rates of hypertension. For 
whites, a medical history of diabetes or both diabetes and hypertension was also significantly 
associated with increased risk of stroke (OR 2.1, 95% CI [1.5 - 3.0], OR 4.5, 95% CI [3.5 - 5.8] 
respectively).  Unlike their African American counterparts, white stroke patients with diabetes 
did have higher rates of elevated cholesterol and MI compared to those without diabetes, in 
addition to higher rates of hypertension.  Based on the data, Kissela and colleagues (2005) 
estimate that 25 to 26% of all ischemic strokes can be attributed to the effects of diabetes, either 
alone or in combination with hypertension; these rates may even underestimate the risk.  
Due to the mortality risk associated with stroke, the prevalence data do not adequately 
represent the magnitude of stroke in the general population (Kuller, 1995).  In the Multiple Risk 
Factor Intervention Trial (MRFIT), 347,978 men aged 35 to 57 years were assessed in 20 centers 
for baseline vital statistics and risk factors from 1973 to 1975, and then observed over a 12-year 
period for Cardiovascular Disease (CVD) mortality (Stamler, Vaccaro, Neaton, & Wentworth, 
1993).  Among 5,163 men who reported taking medication for diabetes, 1,092 died (603 from 
CVD) during the 12-year observation period.  Among the 342,815 men not taking medication for 
diabetes, 20,867 died, 8,965 from CVD.  Absolute risk of CVD death was higher for diabetics 
than non-diabetics across all ages, races and risk factor levels; overall rates were three times 
higher when adjusted for age, race, income, serum cholesterol level, systolic blood pressure, and 
reported number of cigarettes/day (p < 0.0001).   For men both with and without diabetes, serum 
cholesterol level, systolic blood pressure, and cigarette smoking were significant predictors of 
CVD mortality.  For diabetic men with higher values for each risk factor and their combinations, 
absolute risk of CVD death increased more steeply than for non-diabetic men, so that absolute 
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excess risk for diabetic men was progressively greater than for non-diabetic men with higher risk 
factor levels (Stamler et al., 1993).  
Lower blood pressure is associated with improved cardiovascular outcomes, including 
reduced risk for nonfatal strokes in diabetics (Air & Kissela, 2007).  These results are consistent 
with other studies that have found the risk of stroke in diabetics to be directly related to other risk 
factors, especially blood pressure, smoking and dyslipidemia (Air & Kissela, 2007).  However, 
the effect of glycemic control on risk of stroke is less certain than the strong relationship between 
diabetes and stroke (Air & Kissela, 2007; Kuller, 1995).  Published studies provide conflicting 
evidence.  In the Honolulu Heart Program, the risk of stoke was elevated for non-diabetic 
persons with blood glucose.  From 1965 to 1968, the 12-year risk of stroke was examined in 690 
diabetic and 6,908 non-diabetic men free of coronary heart disease and without histories of 
stroke at the beginning of the study.  In 12 years of follow-up, 62.3 per 1,000 diabetic men and 
32.7 per 1,000 non-diabetic men experienced a stroke. The relative risk of thromboembolic 
stroke for those with diabetes compared to those without diabetes was 2.0 (95% CI [1.4 - 3.0]) 
(Abbott, Donahue, MacMahon, Reed, & Yano, 1987). Among those without diabetes, the 
relative risk of thromboembolic stroke for those at the 80th percentile for serum glucose level 
(199 mg/dL [11.0mmol/L]) compared with those at the 20th percentile (115 mg/dL [6.4 
mmol/L]) was 1.4 (95% CI [1.1 - 1.8]) (Abbott et al., 1987).  In the non-diabetic sample, the 
relative risk of thromboembolic stroke for those with glucose measured in urine compared to 
those without measurable glucose in urine was 2.7 (95% CI [1.6 - 4.5]) (Abbott et al., 1987). 
There was no association between diabetes (or measures of glucose intolerance) and hemorrhagic 
stroke (Abbott et al., 1987).  Diabetes, even in a possibly undiagnosed subset of hyperglycemic 
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individuals, imparts an additional independent risk of stroke unexplained by clinically measured 
risk factors. 
The only clinical trial that has directly evaluated the effect of tight glucose control on 
stoke is the UKPDS (UKPDS 33, 1998). T2DM patients in the intensive treatment group 
(average A1C 7.0%) had no significant reduction in stroke incidence (p = 0.52) compared with 
those receiving standard medical therapy (average A1C = 7.9%), indicating that tight glucose 
control is not sufficient for preventing strokes (UKPDS 33, 1998).  It is possible that the study 
lacked sufficient power to detect the difference or that the treatment intensity level was not 
sufficient to impact the stroke incidence (Air & Kissela, 2007).   Although there is no clear 
relationship between glycemic control and stroke incidence, diabetics are at increased risk of 
stroke (Air & Kissela, 2007).  The specific mechanisms that underlie the relationship between 
diabetes and stroke require ongoing investigation to provide new methods for prevention and 
treatment. 
2.2.4 Renal disease (RD) 
Diabetes mellitus is the primary cause of renal disease in nonelderly American adults (Perneger 
et al., 1994), and insulin-dependent diabetics are four times more likely to be diagnosed with 
end-stage renal disease than non-insulin dependent diabetics (Perneger et al., 1994).   Diabetic 
nephropathy occurs in both T1DM and T2DM, and is the leading cause of renal disease, 
affecting approximately 40% of diabetic patients (Gross et al., 2005; Levin & Rocco, 2007).  It 
increases the risk of death, mainly from cardiovascular causes, and is defined by increased 
urinary albumin excretion (UAE) in the absence of other renal diseases (Gross et al., 2005).  
Hyperglycemia, increased blood pressure levels, and genetic predisposition are the main risk 
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factors for the development of diabetic nephropathy.  Elevated serum lipids, smoking habits, and 
the amount and origin of dietary protein are also risk factors, though to a lesser degree.  
Increased urinary protein excretion is the earliest clinical manifestation of diabetic 
nephropathy (Levin & Rocco, 2007).  The development of microalbuminuria usually begins five 
to 15 years after the onset of diabetes in patients with T1DM and then increases over time.  In a 
systematic review of nine longitudinal studies examining microalbuminuria in 7,938 patients 
with TIDM, microalbuminuria was associated with increased long-term mortality.  The relative 
risk for all cause mortality was 1.8% (95% CI [1.5 - 2.1]) compared to patients with normal 
albuminuria (Newman et al., 2005). 
The prevalence of microalbuminuria in patients with T2DM approximately 10 years after 
diagnosis ranges from 25 to 40% (Adler et al., 2003; Gross et al., 2005; Levin & Rocco, 2007).  
The prevalence of microalbuminuria varies with ethnicity, with Asians and Hispanics having a 
higher prevalence than whites (Young et al., 2005). In a cross-sectional study of diabetics with 
uniform access to care, among those without hypertension, Asians were twice as likely to 
develop microalbuminuria (OR 2.01, 95% CI [1.14 - 3.53]) and three times more likely to 
develop macroalbuminuria (OR 3.17; 95% CI [1.09 - 9.26]) than whites (Young et al., 2005).  
Among those with hypertension, adjusted odds of microalbuminuria were greater for Hispanics 
(OR 3.82, 95% CI [1.16 - 12.57]) than whites, whereas adjusted odds of macroalbuminuria were 
threefold greater for blacks (OR 3.32, 95% CI [1.26 - 8.76]) than for whites (Young et al., 2005).     
Some patients with T2DM have microalbuminuria at the time of diagnosis (Adler et al., 
2003).  A possible explanation for the presence of microalbuminuria at the time of T2DM 
diagnosis is previously undiagnosed diabetes or some other pathology. The UKPDS, which 
studied approximately 5,100 patients with newly-diagnosed T2DM, reported that 6.5% of the 
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cohort had microalbuminuria and 0.7% had macroalbuminuria at the time of diagnosis.  From 
diagnosis of T2DM, the progression to microalbuminuria occurs at 2.0% per year, and from 
microalbuminuria to macroalbuminuria at 2.8% per year (Adler et al., 2003). 
2.2.5 Other complications 
2.2.5.1 Hypertension 
Hypertension occurs approximately twice as frequently in diabetics than in people without the 
disease (Sowers, Epstein, & Frohlich, 2001).  Approximately 25% of individuals with T1DM 
and more than 50% of individuals with T2DM have hypertension (Rodbard et al., 2007).  
However, recent data suggest that hypertensive persons are more predisposed to the development 
of diabetes than normotensive persons (Sowers et al., 2001).  In a large, prospective cohort study 
that included 12,550 adults, the development of T2DM was almost 2.5 times as likely in persons 
with hypertension than in their normotensive counterparts (Gress, Nieto, Shahar, Wofford, & 
Brancati, 2000).  Overall, research suggests that diabetes and hypertension, two common chronic 
diseases, frequently coexist (Sowers et al., 2001).  Furthermore, the pathology of each chronic 
disease entity, although independent in its own natural history, serves to exacerbate the other 
(Sowers & Epstein, 1995; Sowers et al., 2001).     
There is a close relationship between hypertension and increasing albuminuria in 
diabetics.  A study of 981 patients who had T1DM for five or more years reported hypertension 
in patients with normoalbuminuria (19%), microalbuminuria (30%) and macroalbuminuria 
(65%) (Parving et al., 1988).  The findings are different in patients with T2DM.  In  a cross-
sectional study of 3,500 newly diagnosed T2DM patients recruited for the UKPDS,  39% (35% 
of the males and 46% of the females) were hypertensive (i.e., had mean blood pressure ≥ 160 
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mm Hg systolic and/or  ≥  90 mm Hg diastolic at two and nine months after diagnosis of 
diabetes, or received antihypertensive therapy) (Turner et al., 1993).  The hypertensive patients 
also had a greater mean body mass index (30.1 versus 28.0 kg/m2, p < 0.0001) than the 
normotensive patients (Turner et al., 1993), showing a relationship with obesity.   
Hypertension also represents a serious risk for diabetics because it amplifies the effects of 
hyperglycemia in producing microvascular complications (Rodbard et al., 2007).  For 
macrovascular complications such as stroke and ischemic heart disease, hypertension is a more 
clinically significant risk factor than hyperglycemia itself (Adler et al., 2000).    
2.2.5.2 Diabetic retinopathy 
Diabetic retinopathy is an increasingly important cause of visual loss.  The National Health and 
Nutrition Examination Survey (NHANES) reported that 11% of patients aged 20 years and older 
with diabetes have visual impairment (Zhang et al., 2006).  The prevalence of diabetic 
retinopathy increases with the duration of diabetes (Klein, Klein, Moss, Davis, & DeMets, 1984).  
Additional risk factors include glycemic control, the type of diabetes (type 1 more than 2), and 
the presence of associated conditions such as hypertension, smoking, nephropathy, dyslipidemia, 
and pregnancy.  Impairments are usually correctable with prescription glasses or contact lenses; 
nonetheless, data support the need for vision screening in addition to dilated eye examinations 
for retinopathy among diabetics. 
2.2.5.3 Diabetic neuropathy 
Foot problems are an important cause of morbidity in patients with diabetes mellitus. Among 
persons diagnosed as having diabetes mellitus, the prevalence of foot ulcers is four to 10% 
(whereas the annual population-based incidence is 1.0 to 4.1%), and the lifetime incidence may 
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be as high as 25% (Singh, Armstrong, & Lipsky, 2005).  Several risk factors are predictive of 
ulcers and amputation. The most important are previous foot ulceration, neuropathy (loss of 
protective sensation), foot deformity, and vascular disease (Singh et al., 2005). 
Neuropathy is present in over 80% of patients with foot ulcers (Singh et al., 2005).  
Neuropathy promotes ulcer formation by decreasing pain sensation and perception of pressure, 
causing muscle imbalance that can lead to anatomic deformities and impair the microcirculation 
and the integrity of the skin.  Once ulcers form, healing may be delayed or difficult to achieve, 
particularly if infection penetrates to deep tissues and bone and/or there is diminished local blood 
flow.  The significance of these risk factors was confirmed by the results of a community-based 
study of 1,300 patients with T2DM in the Fremantle Diabetes Study (Davis, Norman, Bruce, & 
Davis, 2006).  The incidence of lower extremity amputation (LEA) was 3.8 per 1,000 patient-
years.  Predictors of amputation were foot ulceration (HR 5.6, 95% CI [1.2 - 25), ankle brachial 
index < 0.9, elevated A1C, and neuropathy.  First-ever LEAs in T2DM patients were associated 
with poor glycemic control, foot ulceration and evidence of microvascular and macrovascular 
disease.  Patients with LEA were also at increased risk of cardiac death (Davis et al., 2006). 
 
2.3 INTERVENTIONS 
Effective management of diabetes requires persistent monitoring and therapy adjustment (Turner 
et al., 1995).  Findings from large randomized controlled trials provide evidence that intensive 
treatment of diabetes mellitus and conditions known to be risk factors can significantly decrease 
the development and/or progression of chronic complications (DCCT, 1993, 1996; EDIC, 1999; 
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ETDRS, 1991; Goldberg et al., 1998; Knowler et al., 2002; Litzelman et al., 1993; Mann, 2000; 
Ohkubo et al., 1995; Rodbard et al., 2007; Stratton et al., 2000; UKPDS 33, 1998; UKPDS 38, 
1998; UKPDS 40, 1998).  Specific benefits are derived by monitoring and controlling glycemia, 
blood pressure and lipids, screening for microalbuminuria and retinopathy, and conducting 
routine foot examinations (Saaddine et al., 2006).  To achieve greater risk reduction, the 
American Diabetes Association, the American Association of Clinical Endocrinologists, and the 
Diabetes Quality Improvement Alliance recommend more aggressive interventions at earlier 
stages in the disease process (American Diabetes Association, 2010; Feld, Hellman, & Dickey, 
2002; Fleming et al., 2001).  Such treatments include:  (a) lifestyle modifications, such as dietary 
changes, weight reduction, exercise, and smoking cessation; (b) pharmacologic treatments, such 
as statins that effectively prevent both primary and secondary cardiovascular events and decrease 
mortality; (c) intensive control of glycemia and hypertension; and (d) aspirin as a secondary 
prevention for vascular events. 
2.3.1 Glycemic control 
Although diabetes is treated and managed using a multifaceted approach to address both primary 
causes and complications of the disease, glycemic control remains a primary focus in any 
treatment plan.  Much research has focused on glycemic control and its role in mitigating 
complications associated with diabetes.  New pharmacologic therapies and treatment 
technologies safely and effectively lower blood glucose to near-normal levels (American 
Diabetes Association, 2010; Rodbard et al., 2007).  In addition to new rapid-acting and long-
lasting insulin analogs, new medications have been introduced to address recently identified 
pancreatic hormone and incretin hormone deficiencies (Kendall et al., 2005; Rodbard et al., 
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2007; Samsom et al., 2000).  These new medications and similar therapies in development 
effectively lower A1C levels, thereby reducing glycemic variability and weight (Kendall et al., 
2005; Samsom et al., 2000).  Technical advances such as continuous blood glucose monitoring 
mechanisms and insulin pumps provide clinicians and patients with useful tools to monitor and 
adjust treatment regimens (Rodbard et al., 2007). 
2.3.1.1 Glycemic control and microvascular complications 
Hyperglycemia is an important risk factor in the development of microvascular disease, and 
several major studies have found that intensive glycemic monitoring and control significantly 
reduces microvascular complications (DCCT, 1993, 1996; Duckworth et al., 2009; Klein, 1995; 
Margetts, 1995; Nathan et al., 2005; Newman et al., 2005; Phillips & Molitch, 1995; UKPDS 33, 
1998).  The UKPDS study assessed different treatment regimens on glycemic control and 
diabetes complications in 4,000 newly diagnosed patients with T2DM (Holman, Cull, Fox, & 
Turner, 1995).  Over a period of 10 years, average A1C values were lower in the intensive 
therapy group, and the risk for any diabetes related endpoint was 12% lower (p = 0.029), with 
most of the risk reduction being due to a 25% risk reduction in microvascular disease (p = 0.001) 
(Margetts, 1995; UKPDS 33, 1998).  In addition, there was no evidence of a threshold effect for 
A1C; a 1% decrease in A1C was associated with a 35% reduction in microvascular disease 
outcomes (Margetts, 1995; UKPDS 33, 1998).  The benefits of intensive therapy appeared to be 
independent of the type of treatment administered.  Furthermore, the results of the UKPDS post-
trial monitoring phase show that for newly diagnosed T1DM patients, sustained glycemic control 
provides a lasting benefit of reducing microvascular disease (UKPDS 33, 1998).  Notably, 
although A1C values decreased along with microvascular disease risk, there was no statistically 
significant reduction in macrovascular disease (UKPDS 33, 1998). 
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As in the UKPDS, compliance with targets established for glycemic control was found to 
prevent the onset and progression of microvascular complications from diabetes such as 
nephropathy, retinopathy, and neuropathy (DCCT, 1993, 1996; DCCT/EDIC, 2000; Phillips & 
Molitch, 1995).  A 1% reduction in A1C was found to reduce microvascular complications by 
30% (DCCT, 1993).  
The Pittsburgh Epidemiology of Diabetes Complications (EDC) study was an 
observational study of patients with T1DM (Nathan et al., 2009).  The study population consisted 
of the DCCT T1DM cohort (N = 1,441) and a subset of the EDC cohort (n = 161) selected to 
match DCCT entry criteria.  In the DCCT, intensive therapy aimed for a near-normal glycemic 
level with three or more daily doses of insulin.  Conventional therapy, with one to two daily 
doses of insulin, was not designed to achieve specific glycemic targets.  Main outcome measures 
included incidences of diabetic retinopathy, nephropathy (albumin excretion rate > 300 mg/24 h 
or renal replacement), and cardiovascular disease (Nathan et al., 2009).  After 30 years of 
observation, the cumulative incidences of diabetic retinopathy, nephropathy, and cardiovascular 
disease were 50%, 25%, and 14%, respectively, in the DCCT conventional treatment group, and 
47%, 17%, and 14%, respectively, in the EDC cohort (Nathan et al., 2009).   The DCCT 
intensive therapy group had substantially lower cumulative incidences (21%, 9%, and 9%) and 
less than 1% became blind, required kidney replacement, or had an amputation related to 
diabetes during that time (Nathan et al., 2009).  The EDC study provides further evidence that 
the frequency of serious complications in patients with T1DM who are treated intensively are 
lower than previously reported. 
The Veteran’s Affairs Diabetes Trial of Glycemic Control and Complications in Diabetes 
Mellitus Type 2 (VADT) was a longer term prospective study of 1,791 veterans with T2DM 
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(Duckworth et al., 2009).  Diabetics were randomly assigned to either intensive or conventional 
therapy.  The treatment goal for the intensive therapy group was to achieve normal A1C 
measurements.  After an approximate five-year observation period, the intensive therapy group 
achieved an average A1C measurement of 6.9% (HR = 1.07, 95% CI [0.74 - 1.05]) compared to 
the conventional therapy group, with an average A1C measurement of 8.4%; however, there was 
no difference in the first occurrence of any cardiovascular event (such as stroke, death from other 
cardiovascular causes, heart failure, surgery for vascular disease, or amputation) between the two 
treatment groups (Duckworth et al., 2009). 
The results of both UKPDS studies and the DCCT are consistent: intensive therapy 
decreases outcomes of microvascular disease (DCCT, 1993, 1996; DCCT/EDIC, 2000; 
Duckworth et al., 2009; Margetts, 1995; Nathan et al., 2005; Nathan et al., 2009; Phillips & 
Molitch, 1995; UKPDS 33, 1998).  Such intensive control did not provide the same benefit in the 
VADT, but this may be due to the fact that participants had been diagnosed with diabetes for a 
longer period of time (mean of 11.5 years compared to newly diagnosed in UKPDS) and time is 
required to yield benefits, requiring longer follow up, and intensive treatment of hypertension 
and hyperlipidemia (Duckworth et al., 2009). 
Complying with targets established for glycemic control reduces the risk of early onset 
and progression of microvascular complications from diabetes such as nephropathy, retinopathy, 
and neuropathy (DCCT, 1993; DCCT/EDIC, 2000; Mohamed, Gillies, & Wong, 2007; Newman 
et al., 2005; Phillips & Molitch, 1995; UKPDS 33, 1998).   
2.3.1.2 Glycemic control and macrovascular complications 
Several studies suggest a correlation between chronic hyperglycemia and higher rates of 
macrovascular complications (i.e., cardiovascular disease) (Gerstein et al., 2007; Kelly et al., 
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2009; Selvin et al., 2004).  In Selvin’s (2004) meta-analysis of thirteen prospective studies, for 
every 1% increase in A1C, the relative risk for any cardiovascular event is 1.18 (95% CI [1.10 - 
1.26]).  Although these studies suggest that improvements in A1C may reduce cardiovascular 
outcomes, most randomized clinical trials have not demonstrated a beneficial effect of intensive 
therapy (Duckworth et al., 2009; Margetts, 1995; UKPDS 33, 1998).  The VADT trial was 
designed to study the effects of intensive versus conventional therapy on cardiovascular 
outcomes in subjects with longstanding diabetes (average duration eight to 12 years); results 
show no benefit in macrovascular outcomes from intensive control (Duckworth et al., 2009).  In 
fact, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial actually showed a 
significant increase in total and CAD-related mortality with intensive therapy (Buse et al., 2009; 
Gerstein et al., 2007). 
However, meta analyses have demonstrated a reduction in the risk of heart disease (RR 
0.89, 95% CI [0.81 - 0.96]) and non-fatal MI (RR 0.84, 95% CI [0.75 - 0.94]) with intensive 
decreases in blood glucose versus standard treatment (Kelly et al., 2009; Ray et al., 2009).  
Nathan and colleagues (2005) report that early and aggressive glycemic control in patients with 
T1DM lowers the risk for cardiovascular disease by 50%.  There is no glycemic threshold for the 
reduction of complications in T1DM; essentially, the better the control, the lower the risk 
(Stratton et al., 2000).  Klein (1995) also found that glycemic control is associated with lower 
risk of CAD and other macrovascular diseases. 
The contradictory findings in studies on T2DM may be due to differences in study 
designs, pharmacologic therapy choices and baseline glycemic control.  In newly diagnosed 
patients with T2DM, glycemic control as measured by A1C is achievable; however, its role in 
preventing or reducing macrovascular complications is uncertain.  Although advances have been 
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made in the ability to reduce cardiovascular morbidity and mortality in patients with diabetes 
mellitus, the average risk reduction is only 25 to 35%, and patients are still at significant residual 
risk for cardiovascular disease (Rodbard et al., 2007).    
2.3.2 Microalbuminuria screening 
Screening for microalbuminuria is important, as it predicts later development of diabetic 
nephropathy. Even so, individuals with macroalbuminuria are more likely to die in any year than 
to develop renal failure (Adler et al., 2003).  This is partially due to the fact that 
microalbuminuria is also associated with arterial hypertension, diabetic retinopathy, blindness, 
and peripheral neuropathy.  Microalbuminuria can be both a symptom and a predictor of 
complications. For instance, microalbuminuria is a predictor of diabetic nephropathy, and 
patients with increasing nephropathy experience increasing risk of cardiovascular death (p <  
0.0001), with an annual rate of 0.7% for subjects in the stage of no nephropathy, 2.0% for those 
with microalbuminuria, 3.5% for those with macroalbuminuria, and 12.1% with elevated plasma 
creatinine (Adler et al., 2003).  Thus, urinary excretion of albumin should be monitored routinely 
in patients with insulin dependent diabetes (Parving et al., 1988). 
Screening for microalbuminuria should be performed yearly, starting five years after 
diagnosis for patients with T1DM, or earlier in the presence of puberty or poor metabolic 
control.  In patients with T2DM, screening should be performed at diagnosis and yearly 
thereafter.  Patients with micro- and macroalbuminuria should undergo an evaluation regarding 
the presence of other comorbidities, especially retinopathy and other evidence of macrovascular 
disease (Levin & Rocco, 2007). 
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Treating microalbuminuria is complex and multi-faceted.  Achieving high metabolic 
control (A1C  <  7%), treating hypertension (<130/80 mm Hg or <125/75 mm Hg if proteinuria > 
1.0 g/24 h and increased serum creatinine), using drugs with blockade effects on the renin-
angiotensin-aldosterone system, and treating dyslipidemia (LDL cholesterol < 100 mg/dl) are 
effective strategies for preventing the development of microalbuminuria, delaying the 
progression to more advanced stages of nephropathy, and reducing cardiovascular mortality in 
patients with T1DM and T2DM (Gross et al., 2005; Levin & Rocco, 2007).   Research results are 
variable regarding the efficacy of ACE inhibitors or ARBs for the primary prevention of 
microalbuminuria in clinical trials with T2DM patients (Parfrey, 2009; Strippoli, Craig, Schena, 
& Craig, 2005).  
2.3.3 Lipid control 
Aggressive lipid management is important in reducing morbidity and mortality in diabetics.  
While treatment for individuals with diabetes has traditionally focused on glycemic control to 
reduce vascular complications, there is growing evidence highlighting the importance of 
controlling cholesterol levels (Saydah et al., 2004).  Good lipid control can reduce the risk of 
coronary heart disease by 25 to 55% and risk of death by 43% (Goldberg et al., 1998).   
Studies have observed differences in the lipid profiles of T1DM and T2DM patients and 
between diabetics and non-diabetics that may contribute to the increase in CAD.  The lipid 
pattern in patients with T1DM is largely related to glycemic control.  The DCCT found that 
patients with T1DM (mean A1C of 8.8%) had serum lipid values similar to those of non-
diabetics in the Lipid Research Clinics (LRC) prevalence study, except for young women, who 
had somewhat higher serum total cholesterol and lower high-density lipoprotein (HDL) 
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cholesterol concentrations (DCCT, 1992).  Lipid and lipoprotein levels in the generally healthy 
IDDM volunteers for the DCCT were similar to those in the non-diabetic population (DCCT, 
1992).  Insulin resistance, insulin deficiency and obesity are associated with elevated 
triglycerides and low serum HDL cholesterol concentrations and high LDL cholesterol in T2DM 
(O'Brien, Nguyen, & Zimmerman, 1998). 
The association of elevated LDL cholesterol with cardiovascular risk in many 
epidemiologic studies has been reinforced by randomized clinical trials showing that statin 
therapy improves outcomes in diabetics, including those without clinical evidence of CAD and 
those with values below 116 mg/dL (3 mmol/L) (Rodbard et al., 2007).  The primary goal is to 
reduce the LDL-C level to less than 100mg/dL; in high risk individuals, the LDL goal is less than 
70 mg/dL (Rodbard et al., 2007).  Cardiovascular markers such as C-reactive protein and 
lipoprotein associated phospholipase A2 may assist in identifying high risk patients and initiating 
preventive measures (Rodbard et al., 2007). 
2.3.4 Other interventions 
2.3.4.1 Hypertension control 
The results of multiple large randomized controlled trials indicate that blood pressure control 
also reduces morbidity and mortality among diabetics (Adler et al., 2000; Saydah et al., 2004); in 
fact, just a 10 mm Hg reduction in blood pressure reduces macrovascular and microvascular 
complications and risk of death by 35% (UKPDS 33, 1998; UKPDS 38, 1998).  Up to 75% of 
vascular disease in diabetes may be attributable to hypertension, leading to recommendations for 
more aggressive treatment (i.e., reducing blood pressure to < 130/85 mm Hg).  
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 All hypertensive diabetics benefit from lowering blood pressure (Gross et al., 2005; 
Newman et al., 2005).  The prevalence and time of development of hypertension varies for 
T1DM and T2DM patients.  ACE inhibitors and ARBs are often prescribed for hypertension, and 
have been found to reduce disease progression and mortality. 
It is important to note that some studies on non-diabetic hypertensive patients have noted 
a higher risk for the development of diabetes when certain medications are taken.  In one study, 
hypertensive patients who took beta blockers had a 28% higher risk of developing diabetes than 
did those who took no medication , whereas those who took thiazide diuretics, ACE inhibitors, or 
calcium antagonists were found not to be at greater risk for subsequent diabetes than were 
patients who were not receiving any antihypertensive medications (Gress et al., 2000).  Other 
randomized prospective trials have not shown an increase in the development of diabetes with 
beta blocker or low-dose diuretic treatment of hypertension (Sowers et al., 2001).  In contrast, 
the HOPE Study reported that ACE inhibitor therapy reduced the propensity of hypertensive 
patients to develop T2DM by 11% and 34% in six- and four-year trials, respectively, suggesting 
that antihypertensive treatment may significantly decrease the risk of diabetes development in 
this population (Sowers et al., 2001; Yusuf et al., 2000).   
2.3.4.2 Retinopathy interventions 
Proper screening (e.g., dilated fundus examination), glycemic and hypertension control, and 
early interventions incorporating both surgical and pharmacologic therapies can help diabetics 
avoid severe vision loss associated with diabetic retinopathy (Mohamed et al., 2007).  Specific 
treatments include:  pan-retinal laser photocoagulation, focal laser photocoagulation and early 
vitrectomy. When conventional treatments fail, intravitreal steroid injections may be considered 
for eyes with persistent loss of vision (Mohamed et al., 2007).  
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2.3.4.3 Neuropathy interventions 
Substantial evidence supports screening all patients with diabetes to identify those at risk for foot 
ulceration. Prevention of diabetic foot ulcers begins with screening for loss of protective 
sensation.  Specialist clinics may quantify neuropathy with biothesiometry, measure plantar foot 
pressure, and assess lower extremity vascular status with Doppler ultrasound and ankle-brachial 
blood pressure indices.  These measurements, in conjunction with patient medical histories and  
physical examinations, enable clinicians to stratify patients based on risk to determine the types 
of interventions required (Singh et al., 2005).  
Educating patients about proper foot care and conducting periodic foot examinations are 
effective interventions to prevent ulceration. Other possibly effective clinical interventions 
include glycemic control optimization, smoking cessation, intensive podiatric care, debridement 
of calluses, and certain types of prophylactic foot surgery (Singh et al., 2005).  The value of 
various types of prescription footwear for ulcer prevention is not clear (Singh et al., 2005). 
 
2.4 CLINICAL CARE PROCESSES AND OUTCOMES 
Optimal diabetes care depends on healthcare providers adhering to evidence-based practice 
guidelines in the delivery of care, and patients adhering to self-management recommendations in 
order to maximize intermediate outcomes and reduce complications (Ward et al., 2004).   
Process measures assess the degree to which providers follow the evidence-based practice 
guidelines (e.g., the percentage of patients with two A1C tests in a year, at least one lipid test in a 
year, at least one screen for microalbuminuria in a year, etc.).  Outcome measures assess the 
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extent of glycemic, lipid, and blood pressure control in patients with diabetes (e.g., the 
percentage of patients with a measured A1C < 7% and a measured low-risk lipid cholesterol 
(LDL) value ≤ 100 mg/dl).  Process and outcome measures are distinct and complementary 
aspects assessing quality of diabetes care, and the relationship between processes of care and 
patient outcomes is a central issue in health services research.     
2.4.1 Process measures 
For most of the 20th century, diabetes care has been suboptimal and varied in the United States 
(Beckles et al., 1998; Engelgau et al., 1998; Fleming et al., 2001; Kenny et al., 1993; Saaddine et 
al., 2006).  Founded in 1997, the National Diabetes Quality Improvement Project developed a 
comprehensive set of measures to assess quality of care for diabetes patients that are now 
considered standard (Fleming et al., 2001).  Annual screenings for lipids and microalbuminuria 
and at least two measurements of A1C are recommended as well as annual flu vaccinations, 
dilated eye exams and biannual foot examinations (American Diabetes Association, 2005).  
These measures were incorporated into the HEDIS, the American Diabetes Association Provider 
Recognition Program, the American Medical Association Diabetes Measures Group, the 
Veterans Administration’s performance monitoring program, and other standards.  With the 
establishment of national performance measures, researchers have been provided with a unique 
opportunity to assess the provision and quality of successful treatment of diabetes and many 
other chronic diseases.   
In terms of adhering to recommended clinical care processes, quality has improved over 
the past 10 years (Saaddine et al., 2006).   Although the level of care in the US continues to fall 
short of what is recommended, annual lipid testing, dilated eye and foot examinations, self-
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monitoring of blood glucose levels, adherence to aspirin therapy and pneumococcal and 
influenza vaccination rates have improved significantly (Saaddine et al., 2006).  Cross-sectional 
observational data on the quality of medical care for six medical conditions including diabetes 
yielded similar results (Jencks et al., 2003). Using three performance indicators from the 
National Committee for Quality Assurance (NCQA) and HEDIS guidelines, the study found that 
the percentage of Medicare fee for service beneficiaries receiving appropriate diabetes 
preventive care services in the median state improved from the first observational period (1997 
to 1999) to the second (2000 to 2001), from 71 to 78% for A1C testing, 69 to 70% for eye exams 
and 57 to 74% for cholesterol testing (Jencks et al., 2003). 
2.4.2 Outcome measures 
Despite well-documented benefits of process improvements in diabetes treatment, the changes in 
intermediate patient outcomes (e.g., sustained control of A1C) are surprisingly minimal (Selby et 
al., 2007).  In fact, diabetes control in American patients deteriorated over the past decade (Koro 
et al., 2004; Rodbard et al., 2007; Saaddine et al., 2006).   The percentage of T2DM patients with 
A1C levels of less than 7% decreased by approximately 20% from 1988 to 2000 (Koro et al., 
2004).  Selby and colleagues (2007) found that among people with diabetes, one in five (2.2 
million) has poor glycemic control (A1C ≥ 9%), two in five (3.6 million) have poor LDL 
cholesterol level control (≥ 3.4 mmol/L or 130 mg/dL), one in three (3.5 million) has poor blood 
pressure control (≥ 140/90 mm Hg), and one in three has not received annual eye (3.2 million) or 
foot (3.1 million) examinations.  In addition, most patients with diabetes in the United States 
have values for intermediate clinical outcomes that exceed target levels:  58% have A1C ≥ 7%, 
66% have LDL levels ≥ 100 mg/dl, and 52% have systolic blood pressure ≥ 130 mm Hg 
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(Saaddine et al., 2006).  In academic-based health care settings, only 7% of patients with T1DM 
or T2DM achieve the three recommended goals for glycemia, lipids, and blood pressure (Grant 
et al., 2005).  These findings are consistent with another recent report (Jencks et al., 2003) 
highlighting the need for continued efforts to improve intermediate outcomes and noting several 
implications for future quality improvement strategies.   
Another study also recognizes a gap between recommended diabetes care and patient 
outcomes (Saaddine et al., 2002).  Saaddine and colleagues (2002) analyzed data from the third 
U.S. National Health and Nutrition Examination Survey (NHANES III) (1988-1994) and the 
Behavioral Risk Factors Surveillance System (BRFSS) (1995).  The analysis revealed that 18.0% 
of participants (95% CI 15.7% to 22.3%) had poor glycemic control (A1C > 9.5%), and 65.7% 
(CI 62.0% to 69.4%) had blood pressure less than 140/90 mm Hg.  Although cholesterol was 
monitored biannually in 85.3% (CI 83.1% to 88.6) of participants, only 42.0% (CI 34.9% to 
49.1%) had LDL cholesterol levels less than the recommended < 130 mg/dL) (Saaddine et al., 
2002).  In addition, persons taking insulin were more likely to have poor glycemic control 
(24.2%, CI 18.3% to 30.1%) than other patients (15.5%, CI 11.6% to 19.4%) (Saaddine et al., 
2002). 
Saaddine and colleagues (2006) later updated their analysis by examining the same data 
(NHANES and BRFF) from 1999 through 2002.  The proportion of diabetics with poor glycemic 
control (A1C > 9%) showed a non-statistically significant decrease of 3.9% (95% CI 2.5% to 
10.4%). Annual lipid testing increased by 8.3% (CI 4.0% to 12.7%), and the proportion of 
patients with fair or good lipid control (LDL cholesterol level > 130 mg/dL) showed a 
statistically significant increase of 21.9% (CI 12.4% to 31.3%), while mean LDL cholesterol 
levels decreased by 0.5 mmol/L (18.8 mg/dL).  Although mean A1C did not change, the 
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proportion of persons with A1C measurements of six to 8% increased from 34.2% to 47.0%.  
The blood pressure distribution did not change. Recent reports using national data also show 
improvement in cardiovascular disease risk factors among people with diabetes between 
NHANES III and NHANES 1999–2000 (Imperatore et al., 2004; Saydah et al., 2004).   
Thus, improvements in lipid control and some improvement in glycemic control have 
occurred, but blood pressure control has not improved (Saaddine et al., 2006).  These findings 
are consistent with the results reported in specific populations and health care systems, such as 
the Veterans Health Administration (Sawin et al., 2004), Indian Health Service (Roubideaux et 
al., 2004), managed care organizations (McClain et al., 2003), and Medicare (Jencks et al., 
2003).   
2.4.3 Summary 
Although it has not been firmly established that early detection of T2DM and intervention 
actually improves long-term outcomes, a computer simulation model of subjects over age 25 
suggests that the cost increases associated with screening and early treatment may be worth it 
(Engelgau et al., 1998).   However, it should be noted that the benefits of early detection in the 
model were derived more from postponement of complications from diabetes than from 
additional life-years.  In other analyses, targeting individuals with hypertension was more 
effective than universal screening, and screening for impaired glucose tolerance and undiagnosed 
T2DM followed by intervention was more cost effective than no screening at all (Gillies et al., 
2008).  
Given the large number of Americans with undiagnosed diabetes mellitus, early detection 
and treatment is imperative to addressing the diabetes epidemic  (Centers for Disease Control 
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and Prevention, 2008; Rodbard et al., 2007).  The most commonly used screening measurements 
for diagnosing T2DM include fasting plasma glucose (FPG), two-hour plasma glucose during an 
oral glucose tolerance test, glycosylated hemoglobin (A1C), and urine glucose.  In June 2009, the 
International Expert Committee issued a consensus report recommending that A1C tests be used 
to diagnose diabetes (Nathan, 2009).  In making the recommendation, the report noted several 
advantages of the A1C screen over glucose testing, including increased patient convenience and 
the correlation of glycosylated hemoglobin levels with retinopathy (Nathan, 2009).  At the same 
time, it should be noted that urine glucose is an insensitive method of screening for diabetes; the 
high rate of false negative results suggests that it is not adequate as a screening test (Andersson, 
Lundblad, & Svärdsudd, 1993).  Additionally, not all patients with glucose in their urine have 
diabetes since it also occurs when defects in renal tubular function exist (Calado et al., 2006).   
Consistent with ADA guidelines (American Diabetes Association, 2010), measurement 
of fasting blood glucose is recommended for individuals aged 45 years or older and those who 
are considered high risk.  High risk individuals are those with body mass indexes (BMI) of 25 
kg/m2 or more, and one or more additional risk factors for diabetes, including:  family history of 
diabetes, personal history of delivering a baby weighing more than nine pounds or gestational 
diabetes, hypertension, dyslipidemia, habitual physical inactivity, or ethnicity (i.e., African 
American, Hispanic, Native American, Asian American and Pacific Islander).   
Microvascular complications of diabetes mellitus affecting the kidneys (Fong et al., 2004; 
Gross et al., 2005), retinas (Fong et al., 2004; Frank, 2004), and nerves (Vinik et al., 2003) may 
be apparent to a medical examiner before a patient experiences any symptoms. While some 
preventive screening and treatment strategies are applicable for all microvascular diseases, others 
are organ-specific.  A program of periodic preventive monitoring can detect asymptomatic 
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disease that may be responsive to specific therapy aimed at interrupting disease progression or 
reversing the abnormality (Gæde, Vedel, Parving, & Pedersen, 1999; Klein et al., 1991; Lewis et 
al., 2001).  Indicators of microvascular complications are:  (a) microalbuminuria ≥ 30 mg 
albumin/g; (b) creatinine and blood pressure ≥ 130/80 mm Hg (c) use of angiotensin-converting 
enzyme (ACE) inhibitors, which delay the progression of nephropathy in patients with T1DM 
who have hypertension and any degree of albuminuria (Bakris et al., 2000); and (d) the use of 
angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARBs), which may 
slow the progression of microalbuminuria in patients with T2DM, hypertension and renal 
insufficiency (serum creatinine >1.5 mg/dL) (Lewis et al., 2001).  Measuring both processes and 
outcomes contributes to a better understanding of how to improve the quality of diabetes care; 
yet a review of 41 studies on diabetes management in primary care, outpatient and community 
settings, shows that only 15 reported both patient outcomes and process measures (Renders et al., 
2001).  Measuring care processes and patient outcomes in isolation yields incomplete results and 
ignores important implications for diabetes care; the two should not be separated. 
Although the quality of diabetes care appears to be increasing, opportunities remain for 
further improvement.  It is important to note that the percentages of self-reported performance 
measurements obtained from member surveys are almost always higher (sometimes substantially 
higher) than the percentages based on medical record abstracts or administrative data (Fowles, 
Rosheim, Fowler, Craft, & Arrichiello, 1999).  Self-report performance measurements likely 
contributed to statistical improvements in the quality of diabetes care in the United States over 
the past 10 years.   It is important to continue to study adherence to recommended processes and 
patient outcomes together to truly assess improvement and to make better recommendations for 
diabetes care in the future. 
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2.5 ACCESS TO CARE 
The availability of health insurance is a strong factor associated with better process and outcome 
measures (Saaddine et al., 2002).  In a major study, after controlling for age, sex, ethnicity, 
education, insulin use and duration of diabetes, insured persons were less likely to have A1C 
levels greater than or equal to 9.5% (Saaddine et al., 2002).  In the United States, where per 
capita health care costs are the highest in the world and continue to escalate, health insurance has 
become almost essential to accessing appropriate diabetes care.  Reasonable access to health care 
depends on many factors, including the availability of health services in a community and 
personal care-seeking behavior.  However, these and other factors are often trumped by whether 
a person can afford the costs of needed care.  
Health insurance enables access to care by protecting individuals and families against the 
high and often unexpected costs of medical care and connecting them to networks and systems of 
health care providers (Hoffman & Paradise, 2008).  Although private and public health insurance 
plans are available in the United States, the American health insurance system is largely 
comprised of employer-based coverage for working adults and Medicare for the elderly and 
disabled.  
Most working age adults obtain health coverage for themselves and their dependents as a 
benefit of employment.  However, this benefit has been eroding gradually as health premiums, 
along with higher health care costs, grow at rates outpacing general inflation and wages 
(Hoffman & Paradise, 2008; Institute of Medicine Committee on Health Behavior, 2001).  In 
2005, just 61% of the nonelderly had insurance through an employer, down from 66% in 2000 
(Hoffman & Paradise, 2008).  Not surprisingly, low-wage employees are far less likely than 
higher-wage employees to have access to job-based coverage (Hoffman & Paradise, 2008).  In 
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2003, more than half of employees in poor families and more than a third of those in near-poor 
families had no job-based coverage available for their families (Clemans-Cope, Garrett, & 
Hoffman, 2006).  Even when it is available, health insurance is often unaffordable for low-
income people (Clemans-Cope et al., 2006; Kaiser Commission on Medicaid and the Uninsured, 
2007).   
Health services research shows a strong association between health insurance coverage 
and access to primary and preventive care, the treatment of acute and traumatic conditions, and 
the medical management of chronic illnesses such as diabetes (Hoffman & Paradise, 2008).  The 
same research connects being uninsured with adverse health outcomes, including declines in 
health and functioning, the existence of preventable health problems, severe disease at the time 
of diagnosis, and premature mortality (Hoffman & Paradise, 2008; Institute of Medicine, 2002).   
Although health insurance alone would neither eliminate disparities in access to health care nor 
equalize health across subgroups of Americans, having health insurance is clearly connected to a 
longer life of better quality (Institute of Medicine, 2002). 
Disparate access to quality health care is a common explanation for socioeconomic and 
ethnic disparities in diabetic complication rates within the US population (Selby et al., 2007; 
Smedley et al., 2002).  Population-based studies suggest that racial and ethnic minorities and 
people of lower socioeconomic status (SES) experience worse long term diabetes outcomes  than 
whites and people of higher SES (Brown et al., 2005).  Other studies have shown less adherence 
to processes of diabetes care (dilated retinopathy, etc) and worse intermediate outcomes among 
racial and ethnic minorities and individuals with lower incomes or education levels (Karter et al., 
2002; Lanting, Joung, Mackenbach, Lamberts, & Bootsma, 2005).  Since racial and ethnic 
minorities and poorer people with diabetes are less adequately insured than whites or people 
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higher on the SES ladder (Brown et al., 2005), differential access to care may contribute to these 
observations.  Research from managed care settings (Karter et al., 2002; Martin et al., 1995) and 
the Veterans Health Administration (Heisler et al., 2003; Young et al., 2003) suggest that racial 
and ethnic disparities in diabetes processes and outcomes may be reduced in settings offering 
more uniform access to care.  In the TRIAD research, 7,456 adults who were enrolled in health 
plans participated in a six center cohort study on diabetes treatment and outcomes in a managed 
care setting; minority race and ethnicity were consistently associated with worse processes or 
outcomes (Brown et al., 2005).   
It is unknown whether recent improvements in health care options for diabetes have 
benefited all groups equally, or whether, as noted in earlier studies (Karter et al., 2002), 
socioeconomic differences that lead to substandard health care for minorities remain.  However, 
it is clear that access to care and associated variables such as SES and ethnicity are conflated 
with quality of diabetes care in many research studies using participant samples from the general 
population. Thus, studies of insured populations provide an important complement to population 
based studies by controlling for access to care.  
 
2.6 RESEARCH JUSTIFICATION 
Changing demographics in the US population will only fuel the diabetes epidemic, and many 
more people will be stricken with the disease in the years to come (Centers for Disease Control 
and Prevention, 2008).  Ensuring access to and delivery of high-quality care for all people with 
diabetes should be a national priority, as it has serious financial and social implications.  
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Understanding how to better implement existing diabetes care interventions with minimal 
resources will be critical to ensuring the highest possible quality of life for millions of Americans 
afflicted with the disease.  
Understanding diabetes risk factors is challenging, yet essential for preventing diabetes 
complications.  Most of the diabetes care literature focuses on adherence to patient care 
processes or patient outcomes – not both (Renders et al., 2001).  Despite advances in diabetes 
research and consensus recommendations for diabetes care, adherence to patient care processes 
and intermediate health outcomes are still falling short of targeted levels (Saaddine et al., 2006; 
Saaddine et al., 2002).  Many large, cross-sectional studies have been conducted on samples 
drawn from the general population without controlling for access to care (i.e., health insurance 
coverage).  At the same time, ethnicity has been shown to play a role in diabetes complications, 
but it is not known whether genetics have an impact or whether effects are secondary and 
associated with access to care – and by extension, socioeconomic status.   
A few studies have tried to examine the joint effect of these problems.  Karter and 
colleagues (2002) reported ethnic differences for five major complications observed in a three 
year longitudinal study of a diabetic population with uniform health care coverage.  The patterns 
of ethnic differences were not consistent across complications and frequently persisted, despite 
adjustment for a wide range of demographic, socioeconomic, behavioral and clinical factors.  
The persistence of ethnic disparities after adjustment suggests possible origins related to 
genetics, unmeasured environmental factors, or a combination of the two (Karter et al., 2002).   
Regardless, even people with apparently good access to health services receive care that 
falls far short of what it could be (Jencks et al., 2003).  Healthy People 2010, a document created 
by the US Department of Health and Human Services confirm wide gaps between public health 
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performance and actual outcomes based on many quality indicators (Jencks et al., 2003; US 
Department of Health and Human Services, 2010).  In a recent effort to underscore the need for 
an expanded agenda of public health, a framework was created with the goal of eliminating 
disparities and improving adult health; it consists of five broad research focus areas: genetic 
predispositions, behavioral factors, social circumstances, physical environmental factors, and 
shortfalls in medical care (McGinnis, Williams-Russo, & Knickman, 2002).  Such social and 
environmental pathways must be understood well enough to permit the development of effective 
chronic disease control strategies for large organizations including employers and government 
(Ver Ploeg & Perrin, 2004). 
 Consistent with the framework put forth by McGinnis and colleagues (2002),  this study 
examines baseline predictors of diabetes outcomes among an ethnically diverse working 
population of diabetics with uniform health care benefits.  The goal is to provide a better 
understanding of risk factors associated with personal characteristics by controlling for access to 
care in an ethnically diverse sample.  It may also yield insights into why some patients are not 
yet benefiting fully from quality improvement efforts (Jencks et al., 2003; US Department of 
Health and Human Services, 2010), and inform the design or revision of disease management 
programs and process of care measures. 
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3.0  METHODS 
3.1 STUDY HYPOTHESIS 
The central hypothesis of this study is that quality of diabetes care is associated with reducing the 
risk of coronary artery disease (CAD), heart failure (HF), Stroke (ischemic or hemorrhagic), and 
renal disease (RD).  The analysis examines the relationships between three quality of diabetes 
care measures and the risk of macrovascular and microvascular complications in a sample of 
diabetics employed by a US manufacturer with uniform healthcare benefits and access to 
healthcare.  Measures of quality of diabetes care include A1C tests, lipid tests and urine 
screening tests for microalbuminuria.  While controlling for potential confounding variables 
(e.g., age, race, gender, income, smoking), the data were analyzed to see if employees who 
received all three quality of diabetes care measures (QOCM) in the baseline year demonstrated a 
lower risk for developing any of the four primary complications associated with diabetes over the 
six-year observation period.  Since it was anticipated that individual employee characteristics 
would impact outcome risk, data on age, gender, ethnicity, marital status, income, insulin use, 
co-morbidities as measured by health severity risk score, and lifestyle behaviors such as smoking 
were collected.  
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3.1.1 Study design 
A retrospective cohort study was conducted from January 1, 2003 to December 31, 2009 and 
included a baseline year (2003) and a six-year observation period (2004 through 2009).  The 
study setting was a US-based, global manufacturing company with approximately 36,000 
employees working in 22 states during the years of the study.  Most employees held hourly 
manufacturing jobs, and minorities and women were well represented.  Employees selected from 
a menu of health benefits in terms of costs and deductibles, however only a single Preferred 
Provider Organization (PPO) network was available to the entire population; Health 
Maintenance Organization (HMO) alternatives were offered only at a few locations.  Because the 
offered plans were comprehensive in coverage, less than 3% of the employees and their families 
opted out of health insurance.  Eligible participants were employed by the manufacturer in 2001 
and 2002 and at least one month in the observation period (2003 through 2009), between 18 and 
64 years old, and had submitted a medical claim for one of the following: one hospitalization or 
emergency room visit, two office visits for diabetes (ICD9 250.XXX) or one prescription for a 
diabetes medication.  Women with gestational diabetes were excluded.   
 Quality of diabetes care was measured by the assessing the monitoring frequency for all 
diabetics in 2003, the baseline year.  Quality of care benchmarks (i.e., two A1C tests at least 30 
days apart in the same year, and annual tests for lipids and microalbuminuria) were set based on 
relevant performance reporting measures from the American Diabetes Association at the time 
(Stratton et al., 2003). Diabetics were categorized into two mutually exclusive groups:  those 
who received all of the tests in 2003, and those who did not.  The groups, which were large 
enough to allow for statistical efficiency and power, were compared to assess the differences in 
risk of developing CAD, HF, Stroke, RD or any of the four complications.  The null hypothesis - 
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that the experimental and control survival curves for each of the four complications were equal - 
was rejected, with a probability (power) of 0.886 (CAD), 1.000 (HF), 1.000 (Stroke), 0.985 (RD) 
and 0.976 (any of the four complications).  The Type I error probability associated with the test 
of this null hypothesis was 0.05. Table 1 summarizes the power associated with detecting 
differences in hazard rates for each complication.  Cox proportional hazard regression models 
were used to assess potential associations between diabetes QOCM and time to complication.  
 
Table 1.  Power Associated with Detecting Hazard Rates for Each Complication 
HR 
Power 
CAD CHF Stroke Renal Any 4 
1.1 0.21 0.22 0.22 0.22 0.21 
1.2 0.58 0.61 0.61 0.61 0.58 
1.3 0.86 0.89 0.89 0.89 0.86 
1.4 0.97 0.98 0.98 0.98 0.97 
1.5 1.00 1.00 1.00 1.00 1.00 
 
3.1.2 Data sources 
All data were available as part of a unique academic-corporate partnership that began in 1997 for 
the purpose of developing and implementing workplace safety and occupational health programs 
for the manufacturer.  The research agreement between the university and the manufacturer 
allows investigators to extract information from the company’s electronic databases which are 
then de-identified and linked by the university data manager.  The databases have been described 
in greater detail in previous publications (Cullen et al., 2006).  
Health data were obtained from the health insurance plan, occupational health medical 
record reviews, and other employer-managed administrative databases, described below.   
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1. Health Insurance Claims Database: Investigators receive data on medical and 
pharmacy claims from a central insurance data processing center each year.  The 
central data processing center receives health insurance data from each third party 
administrator.  Data include ICD-9 codes (US National Center for Health Statistics 
and the Health Care Financing Administration, 1987) for disease diagnosis and NDCs 
(National Drug Codes)1 for prescription information.  Data on date of service, 
provider type, and provider location are also available.   
2. Occupational Health Screening: This database provides basic health screening 
information for employees who participate in fitness-for-duty evaluations at the start 
of employment and medical surveillance programs.  Although the extent of screening 
varies by job, all employees in this study participated in at least one medical 
screening program in which smoking status was routinely monitored.  Occupational 
health data were provided to the investigators in one of two ways:  an electronic 
database of data gathered from mandatory health screenings, and data in the 
employees’ occupational health records.  Beginning in 2002, an attempt to collect 
more comprehensive data on employee health risk factors was initiated and a team of 
investigators began extracting health data from medical departments at individual 
plants.  Data collected included smoking history, cholesterol, blood pressure, height, 
weight, education status, and marital status.   
3. Human Resources: Provided annually, this database contains all employee 
demographic information, including date of birth, race and gender.  Files are created 
                                                 
1 The National Drug Code Directory can be found at:  http://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm . 
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at the start of employment and document all changes in job title, job grade, job status 
(active, on leave, retired), job category (hourly or salary), and plant location.   
The National Committee for Quality Assurance’s (NCQA) Healthcare Effectiveness Data 
and Information Set (HEDIS) measures for diabetes were obtained from the Health Insurance 
Data Set.  Diagnostic and outcome measures were obtained from inpatient and outpatient claims 
and pharmacy data provided in the Health Insurance Data Set.  Gender, marital status, ethnicity, 
income, employment status (hourly, salary) were obtained from Human Resources and 
Occupational Health Screening data sets.  These data were used to establish the cohort, tabulate 
quality indicators (e.g., number of diabetes quality of care tests) and link them to complications 
from diabetes.  Vision claims were not available, therefore claims for routine eye exams and 
screening for diabetic neuropathy were not usable as quality of diabetes care measures.   
Processes of diabetes care were measured by assessing the frequency of monitoring for 
all diabetics in the baseline year based on a standard of two A1C tests at least thirty days apart 
and annual tests for lipids and microalbinurea.  The A1C tests, lipid test and screening for 
microalbuminuria were analyzed for collinearity before including them in the model to address 
their association with complications.  Pearson Correlation coefficients ranged from 0.29708 to 
0.60935, p < 0.0001; lipids and A1C were collinear and could not be evaluated independently.  
Microalbuminuria was not strongly correlated with A1C and lipids, with coefficients of 0.34193 
and 0.29708, respectively.  The three measures were combined into a single measure of quality 
of diabetes care to sharpen the between group contrast and reduce the potential for 
misclassification associated with simple dichotomization.  This approach yielded two groups 
based on quality of diabetes care that were compared for potential associations with 
complications (CAD, HF, Stroke or RD).  
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Sightlines DxCG Risk Solutions Software was used to assign risk scores to the cohort and 
capture potential illness-related influences on treatment decisions to manage diabetes.  Risk 
adjustment and predictive models enable healthcare organizations and government agencies to 
analyze, predict and manage risk for their insured populations. DxCG was chosen over the 
Charlson Index (which was developed specifically for Medicare population) because it 
differentiates health risk among commercially insured populations and those on 
Medicare/Medicaid.  It uses validated medical and pharmacy classification systems combined 
with proprietary risk adjustment and predictive models to assign a health severity risk score 
based on gender, age, race, diagnosis and prescription data that are part of the case mix 
adjustment model.   
Cox proportional hazard regression models were used to assess potential associations 
between diabetes quality of care measures and time to one of the four complications.  Potential 
confounding risk factors included in all Cox models were sex, age, ethnic group, income, marital 
status, education, smoking, body mass index, diabetes severity2 and health severity risk scores.   
A sensitivity analysis to assess the effect of continuous optimal care (i.e., at least two 
A1C tests, one microalbuminuria screen and one lipid test) on adverse outcomes was conducted 
for 2003 only and the two-year period of 2003 and 2004 in order to determine the 
appropriateness of the baseline period.  The sensitivity analyses were based on a correlation 
analysis, Kappa statistics and Cox proportional hazard regression models.   
                                                 
2 Insulin use has been closely associated with duration and severity of diabetes (UKPDS 33, 1998).  
Diabetes severity was based on an employee’s first insulin prescription recorded in the study period (Thompson, 
2005). 
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3.2 ETHICS 
Databases were linked by an encrypted unique identifier created by the Yale University 
Occupational and Environmental Medicine Data Manager to ensure human subject privacy.  The 
Yale University School of Medicine IRB approved this study.  
3.3 DIABETES CASE ASCERTAINMENT 
Using eligibility criteria outlined in section 3.1.1, diabetes cases were identified in the sample for 
the baseline year (2003), along with complications occurring anytime during the 72-month 
observation period (2004 through 2009).  If a diabetic had a specific complication in 2001 or 
2002, they were excluded from the analysis.  Diabetics were identified using ICD-9 codes 
250.XX, 3572, 357.2x, 36641, 36201, and 36202.  This definition was expansive, in that it 
included T1DM and T2DM.  If an employee had a prescription for a diabetes drug and did not 
have an ICD-9 code for type, they were coded as T2DM.  Diabetics with medical claims for one 
of the four complications in the baseline year were included in the data set, but were excluded 
from the analysis for the same complication.  For example, if a diabetic had a medical claim with 
an ICD-9 code for a myocardial infarction in 2003, they were included in the data set but 
censored from the CAD analysis only.  This logic was applied to all complications to eliminate 
bias from the analysis, since quality of diabetes care in the baseline year was used to predict new 
complications only.  This approach allowed us to include as many individuals in the study as 
possible.  Using this algorithm, data from 1,797 people were included in the analysis (see Figure 
1). 
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Figure 1.  The baseline cohort for the study. 
3.4 OUTCOME ASCERTAINMENT 
The following ICD-9 codes were used to determine time of onset for any of the four 
complications:  CAD (ICD9 410.XX-414.XX), HF (ICD9 398.91, 428.XX, 402.11, 402.91, 
404.11, 404.13, 404.91, 404.93), Stroke (ICD9 430, 431, 432, 433, 434, 435, 436, 437, 438), and 
RD (ICD9 404.XX, 585, 586 or 403.11, 403.91, 404.12, 404.92, V42.0, V45.1, V56.0, V56.8). 
 
3.4.1 Statistical analysis 
Hazard ratios for outcomes (CAD, HF, Stroke, RD) were calculated for quality of diabetes care 
(exposures) and covariates.  The Kaplan-Meier method was used to identify crude time-to-event 
models for the associations between exposures and outcome variables.  Time-to-event methods 
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were used for all primary analyses.  For a given outcome, the time-to-event was defined as the 
number of months from the start of the observation period (January 1, 2004) to the first medical 
claim for a complication.  Diabetics who no longer received employer-provided health benefits 
were censored at the time of the last medical claim.  Tests for all time-dependent variables were 
not significant, either individually or collectively.  The assumption of proportional hazards was 
visually examined, and there was not enough evidence to reject proportionality.  Thus, the 
assumption of proportionality for this model was satisfied. 
Time-dependent Cox proportional hazard models were used to evaluate bivariate and 
multivariate models, which enabled time-to-outcome assessment and risk adjustment based on 
socioeconomic and lifestyle risk factors (gender, age, race, marital status, salary, and smoking), 
co-morbidities (health severity risk scores), and severity of diabetes (insulin, no-insulin).  Hazard 
ratios for primary outcome comparisons were calculated based on Cox proportional hazard 
analyses stratified by hourly, salary, gender and insulin use.  In addition, Kappa statistics, 
correlation analyses and Cox proportional hazard analyses were used to assess outcome 
differences based on two years (2003 and 2004) of continuous QOCM.  All analyses were 
conducted using SAS software version 9.2.   
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4.0  RESULTS 
4.1 BASELINE CHARACTERISTICS 
A total of 1,797 patients were included in the analysis.  The base model was specified with 
demographics and then groups of related, potentially explanatory variables such as SES, 
modifiable risks and clinical characteristics were added to the demographic model.  First, SES 
indicators such as individual income, job status (hourly or salary), and marital status were 
included, followed by smoking status as a modifiable risk.  Clinical characteristics specific to 
diabetes, such as insulin use and health severity risk score, were then added as measures of co-
morbidities.  Finally, a fully-adjusted model was used to assess the combined explanatory effects 
for all measured factors.  
Baseline characteristics of the sample are presented in Table 2.  The cohort consisted 
primarily of Caucasian (63.7%), male (85.8%), married (76.4%) hourly employees (75.7%), a 
significant number of whom earned less than $35,423 per year (27.2%).  More than half (55.1%) 
were between the ages of 18 and 51.  The mean age for the total population was 49.0 years (sd = 
8.4).  Smoking data was reported as never (14.4%), past/current (17.3%) and unknown (68.3%); 
smoking rates were slightly lower than for the general US population of working men and 
women (21%) (Centers for Disease Control and Prevention, 2008; Cowie, Rust, Byrd-Holt, & 
Eberhardt, 2003).  As a measure of diabetes severity, 23.1% of the population had insulin 
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prescriptions during the baseline year.  Health severity risk scores were used to assess co-
morbidities, with 76.1% of the cohort receiving a score of 2.1 or lower.  For the quality of 
diabetes care measures, 61.8 % of the total population was tested in the baseline year, with 
43.0% receiving at least two A1C tests and 24.0% receiving tests for microalbuminuria.   
 
Table 2.  Demographic Characteristics (2003) 
Characteristic 
Diabetics 
(N = 1797) 
Age n % 
 18 - 45 522 29.0 
 46 - 51 469 26.1 
 52 - 56 469 26.1 
 57- 64 337 18.8 
Gender     
  Male 1494 83.1 
    Female 303 16.9 
Race     
    White 1244 69.2 
    Black 346 19.3 
    Hispanic 166 9.2 
    Other 41 2.3 
Marital Status/Dependents*      
     Married (spouse on health insurance) 1333 74.2 
Compensation     
    Hourly 1361 75.7 
    Salary 436 24.3 
Wage     
    Quartile 1 (< $35,423) 488 27.2 
    Quartile 2 ($35,424 - $44,743) 435 24.2 
    Quartile 3 ($44,744 - $56,903) 444 24.7 
    Quartile 4 (> $56,903) 430 23.9 
Smoking     
    Never 258 14.4 
    Past/Current 311 17.3 
    Unknown 1228 68.3 
Insulin 361 20.1 
Health Severity Risk Score     
    Quartile 1 (≤ 1.0 ) 451 25.1 
    Quartile 2 (1.0 - 1.4) 448 24.9 
    Quartile 3 (1.4 - 2.1) 451 25.1 
    Quartile 4 (≥ 2.1 ) 447 24.9 
Quality of Care Measures     
    A1C (1 tests) 1214 67.6 
    A1C (2 tests) 773 43.0 
   Microalbuminuria 431 24.0 
   Lipids 1110 61.8 
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Table 2 (continued) 
* determined from health insurance eligibility file 
 
4.2 COMPLICATIONS IN THE COHORT 
In total, 24% (n = 366) of the cohort reported a claim for one of the four complications over the 
six-year observation period with a mean time-to-complication of 29.1 months. The most frequent 
complication in the cohort was CAD (16.9%, n = 267) with a mean time-to-complication of 26.6 
months.  RD (4.9%, n = 86) was the least frequent complication in the cohort, and had the 
longest mean time-to-complication of 38.1 months.   
 
Table 3.  Complications in the Cohort (2004-2009) 
Complication 
Diabetics (N = 1797) Mean Time-to- Complication 
(in months) n % 
CAD 267 16.9 26.6 
HF 102 5.8 29.7 
Stroke 152 8.7 33.1 
RD 86 4.9 38.1 
1 or more of the above 366 24.0 29.1 
4.3 QUALITY OF CARE MEASURES 
At baseline, the cohort receiving all three quality of diabetes care measures (QOCM) was smaller 
(n = 267) than the comparison group (n = 1,530).  Statistics for QOCM are shown in Table 4.  
Chi square statistics were performed to assess differences between the two groups.  Despite the 
sample size differences in the cohorts, there were no statistically significant differences between 
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the two study groups during the baseline period (2003) for demographic, SES or modifiable risk 
variables, with the exception of insulin prescriptions in the group that received all three QOCM 
versus the group that received less than all three QOCM, which were 27.7%, n = 74 and 18.8%, 
n = 287, respectively, with p = 0.0007.  Health severity risk scores were also significantly 
different between the two groups (p = 0.0429).   
 
Table 4.  Statistics for QOCM during the Baseline Period (2003) 
Employees with Diabetes (N = 1797) All 3 QOCM 
(n = 267) 
< 3 QOCM 
(n = 1530) p-
value 
Characteristic n % n % 
Age         0.2973 
   18 - 45 75 28.1 447 29.2   
   46 - 51 74 27.7 395 25.8   
   52 - 56 70 26.2 399 26.1   
   57- 64 48 18.0 289 18.9   
Gender         0.2137 
    Male 229 85.8 1265 82.7   
    Female 38 14.2 265 17.3   
Race         0.1525 
 White 170 63.7 1074 70.2   
 Black 59 22.1 287 18.8   
 Hispanic 32 12.0 134 8.8   
 Other 6 2.2 35 2.3   
Marital Status*           
     Married 204 76.4 1129 73.8 0.3679 
Compensation         0.3679 
    Hourly 186 69.7 1175 76.8   
    Salary 81 30.3 355 23.2   
Wage         0.864 
    Quartile 1 (< $35,423) 67 25.1 421 27.5   
    Quartile 2 ($35,424 - $44,743) 65 24.3 370 24.2   
    Quartile 3 ($44,744 - $56,903) 69 25.8 375 24.5   
    Quartile 4 (> $56,903) 66 24.7 364 23.8   
Smoking         0.2495 
    Never 32 12.0 226 14.8   
    Past/Current 41 15.4 270 17.6   
    Unknown 194 72.7 1034 67.6   
Insulin 74 27.7 287 18.8 0.0007 
Health Severity Risk Score         0.0429 
    Quartile 1 (≤ 1.0 ) 50 18.7 401 26.2   
    Quartile 2 (1.0 - 1.4) 67 25.1 381 24.9   
    Quartile 3 (1.4 - 2.1) 71 26.6 380 24.8   
    Quartile 4 (≥ 2.1 ) 79 29.6 368 24.1   
*determined from health insurance eligibility files. 
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4.4 CENSORED DATA 
Of the 901 records censored during the observation period (January 1, 2004 through December 
31, 2009), 647 were due to retirement, layoff or termination.  There were 14 deaths, and 16 
diabetics went on long term disability, but death certificates and detailed disability information 
were unavailable for analysis.  Chi square statistics were performed to assess differences 
between the two groups.  Since most data were censored based on retirement, layoff or 
termination, the statistically significant differences found for age (p < 0.0001) and salary (p = 
0.0001) were expected.  Differences in race, marital status, compensation (salary or hourly), 
insulin use and health severity risk score were not significant.  Most importantly, there was no 
evidence that those whose data were censored had different rates of receiving all three QOCM 
than those whose data were not censored, suggesting censorship as an unlikely source of 
importance bias. 
 
Table 5. Data Censorship Statistics 
 Characteristic 
Censored (n = 901) Not Censored (n = 625) 
p-value 
n % n % 
Age         <.0.0001 
   18 - 45 322 35.7 165 26.4   
   46 - 51 205 22.8 202 32.3   
   52 - 56 207 23.0 163 26.1   
   57- 64 167 18.5 95 15.2   
Gender         0.3267 
    Male 738 81.9 524 83.8   
    Female 163 18.1 101 16.2   
Race         0.4363 
    White 603 66.9 433 69.3   
    Black 190 21.1 111 17.8   
    Hispanic 85 9.4 65 10.4   
    Other 23 2.6 16 2.6   
Marital Status*           
    Married 644 71.5 468 74.9 0.1414 
Compensation         0.514 
    Hourly 673 74.7 476 76.2   
    Salary 228 25.3 149 23.8   
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Table 5 (continued) 
Wage         <.0001 
    Quartile 1 (< $35,423) 283 31.4 127 20.3   
    Quartile 2 ($35,424 - $44,743) 229 25.4 144 23.0   
    Quartile 3 ($44,744 - $56,903) 188 20.9 189 30.2   
    Quartile 4 (> $56,903) 201 22.3 165 26.4   
Smoking         <.0001 
    Never 111 12.3 117 18.7   
    Past/Current 117 13.0 138 22.1   
    Unknown 673 74.7 370 59.2   
Insulin 167 18.5 133 21.3 0.1846 
Health Severity Risk Score         0.1161 
    Quartile 1 (≤ 1.0 ) 261 29.0 174 27.8   
    Quartile 2 (1.0 - 1.4) 267 29.6 156 25.0   
    Quartile 3 (1.4 - 2.1) 216 24.0 171 27.4   
    Quartile 4 (≥ 2.1 ) 157 17.4 124 19.8   
Quality of Care Measures           
    A1C (1 tests) 592 65.7 429 68.6 0.2308 
    A1C (2 tests) 375 41.6 274 43.8 0.3884 
    Microalbuminuria 222 24.6 160 25.6 0.6701 
    Lipids 532 59.0 387 61.9 0.2592 
* determined from health insurance eligibility files 
4.5 COMPLICATIONS 
4.5.1 Coronary artery disease (CAD) 
The most frequent complication in the cohort was CAD (16.9%, n = 267) with a mean time-to-
complication of 26.6 months.  The hazard rate (HR 0.70, 95% CI [0.49 - 1.02], p = 0.0635) was 
lower for diabetics with at least one claim for CAD who received all three QOCM in the baseline 
year relative to diabetics with CAD who did not receive all three QOCM in the baseline year.  
The difference was borderline significant.   
Certain diabetic characteristics were more likely to be associated with developing CAD 
as a complication of diabetes in the multivariate model (see Table 6).  Males (HR 1.72, 95% CI 
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[1.15 - 2.56], p = 0.008) were significantly more likely to develop CAD than females.  Older 
people (aged 46 to 51 years) were also at increased risk for CAD (HR 1.81, 95% CI [1.24 - 2.54], 
p = 0.002).  Smoking, either in the past or during the study, also increased the risk for CAD, with 
a borderline significant hazard rate of 1.47 (95% CI [0.97 - 2.21], p = 0.0676).  In addition, a 
health severity risk score greater than 2.1 was associated with a statistically significant increased risk 
of CAD (HR 2.17, 95% CI [1.47 - 2.19], p < 0.0001).  The health severity risk score includes 
age, gender and comorbidities, and therefore may cause an underestimation of associations with 
co-morbidities.   
 
Table 6.  Multivariate Associations with CAD (2004-2009) 
Characteristic 
All 
(N = 1580) 
Bivariate 
Multivariate 
(demographics, lifestyle, 
QOC, and HSRS) 
n % HR 95% CI p-value HR 95% CI p-value 
Age 
        
    18 - 45 497 31.5 1.00 reference   1.00 reference   
    46 - 51 418 26.5 1.99 1.39 2.84 0.0002 1.81 1.24 2.64 0.002 
    52 - 56 386 24.4 2.26 1.58 3.23 <.0001 1.85 1.25 2.74 0.0022 
    57- 64 279 17.7 3.30 2.25 4.84 <.0001 2.61 1.70 4.00 <.0001 
Gender                     
    Male 1305 82.6 1.55 1.07 2.24 0.0205 1.72 1.15 2.56 0.008 
Race                     
    White 1074 68.0 1.00 reference         
    Black 313 19.8 0.85 0.62 1.17 0.3246 0.92 0.66 1.27 0.6014 
    Hispanic 153 9.7 0.82 0.54 1.25 0.3566 0.87 0.57 1.33 0.5195 
    Other 40 2.5 1.21 0.57 2.56 0.6278 1.14 0.53 2.45 0.729 
Marital Status                     
    Married 1151 72.8 1.13 0.86 1.49 0.3908 0.92 0.69 1.24 0.5921 
Compensation                     
    Hourly 1182 74.8 1.25 0.93 1.68 0.1398 1.24 0.88 1.73 0.2173 
Wage                     
    Quartile 1  (< $35,423) 425 26.9 1.00 reference   1.00 reference   
    Quartile 2  ($35,424 - $44,743) 382 24.2 1.37 0.97 1.93 0.0754 1.19 0.83 1.70 0.3552 
    Quartile 3  ($44,744 - $56,903) 392 24.8 1.14 0.80 1.61 0.4719 0.97 0.66 1.42 0.8778 
    Quartile 4  (> $56,903) 381 24.1 1.15 0.81 1.64 0.4412 0.96 0.63 1.46 0.8499 
Smoking                     
    Never 235 14.9 1.00 reference   1.00 reference   
    Past/Current 265 16.8 1.60 1.07 2.41 0.0229 1.47 0.97 2.21 0.0676 
    Unknown 1080 68.4 1.15 0.81 1.64 0.4276 1.19 0.82 1.71 0.3669 
    Insulin 311 19.7 1.15 0.86 1.54 0.343 1.14 0.84 1.54 0.406 
Health Severity Risk Score                     
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Table 6 (continued) 
    Quartile 1 (≤ 1.0 ) 438 27.7 1.00 reference   1.00 reference   
    Quartile 2 (1.0 - 1.4) 424 26.8 1.38 0.96 2.00 0.0833 1.17 0.79 1.72 0.426 
    Quartile 3 (1.4 - 2.1) 399 25.3 1.62 1.14 2.31 0.0075 1.28 0.87 1.89 0.2134 
    Quartile 4 (≥ 2.1 ) 319 20.2 2.76 1.96 3.88 <.0001 2.17 1.47 3.19 <.0001 
Quality of Care Measures (2003)                     
    All 3 QOCM*  235 14.9 0.76 0.53 1.10 0.1424 0.70 0.49 1.02 0.0635 
 
* 2 A1C measurements, 1 microalbuminuria test, and 1 lipid test in 2003 
4.5.2 Heart failure (HF) 
During the six-year observation period, 102 diabetics had at least one medical claim for HF.  HF 
was the third most frequent complication in the cohort (5.8%), with a mean time-to- 
complication of 29.7 months.  The hazard rate for diabetics who submitted at least one medical 
claim for HF was lower for those who received all three QOCM in the baseline year (HR 0.39, 
95% CI [0.19 - 0.81], p = 0.0118) compared to diabetics who received less than all three QOCM.   
Certain covariates were more likely to be associated with medical claims for HF as a 
complication of diabetes in the multivariate model (see Table 7).  Although rates varied modestly 
among groups by race and gender, neither was statistically significant.  Hazard rates increased 
along with age, which was borderline significant for diabetics aged 46 to 51 years (p = 0.0513) 
and statistically significant for diabetics aged 52 to 56 years (p = 0.0013) and 57 to 64 years (p < 
0.0001).  Smoking, both in the past and during the study, was associated with a more than two-
fold risk for submitting a claim for HF (HR 2.21, 95% CI [1.06 - 4.62], p = 0.00353).  Although 
increasing age and smoking are known risk factors for HF among diabetics (Cowie et al., 2003), 
it has been cited elsewhere that younger age groups are also at increased risk (Nichols, Gullion, 
Koro, Ephross, & Brown, 2004). 
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Health severity risk scores of 2.1 or greater were associated with higher hazard rates than 
those with lower scores (HR 2.05, 95% CI [1.04 - 4.03], p = 0.038).  Ischemic heart disease is 
often comorbid with diabetes, and is an important predictor of HF in diabetics, especially among 
those who use insulin (Nichols et al., 2004).  However, insulin use was not associated with HF 
risk in this cohort.  All other associations were insignificant.  
 
Table 7.  Multivariate Associations with HF (2004-2009) 
Characteristic 
All 
(N = 1765) 
Bivariate 
Multivariate (demographics, 
lifestyle, QOC, and HSRS) 
Age 
n % HR 95% CI 
p-
value HR 95% CI 
p-
value 
   18 - 45 518 29.3 1.00 reference   1.00 reference   
   46 - 51 462 26.2 2.40 1.14 5.03 0.0212 2.15 1.00 4.65 0.0513 
   52 - 56 456 25.8 4.25 2.11 8.57 <.0001 3.42 1.61 7.25 0.0013 
   57- 64 329 18.6 8.47 4.16 17.24 <.0001 6.44 2.96 14.01 <.0001 
Gender                     
   Male 1467 83.1 0.87 0.53 1.43 0.5863 1.01 0.57 1.79 0.9641 
Race                     
   White 1220 69.1 1.00 reference         
   Black 340 19.3 1.34 0.84 2.12 0.2179 1.50 0.93 2.41 0.0961 
   Hispanic 165 9.3 1.02 0.53 1.99 0.949 1.14 0.58 2.25 0.6966 
   Other 40 2.3 0.54 0.08 3.89 0.5403 0.45 0.06 3.28 0.4317 
Marital Status                     
   Married  1308 74.1 1.16 0.73 1.85 0.5312 1.05 0.64 1.73 0.8529 
Compensation                     
   Hourly 1335 75.6 1.31 0.80 2.13 0.2845 1.19 0.68 2.07 0.5503 
Wage                     
   Quartile 1 (< $35,423) 480 27.2 1.00 reference   1.00 reference   
   Quartile 2 ($35,424 - $44,743) 424 24.0 1.34 0.77 2.31 0.3015 1.22 0.69 2.18 0.4952 
   Quartile 3 ($44,744 - $56,903) 438 24.8 1.02 0.58 1.79 0.9559 1.01 0.54 1.90 0.9682 
   Quartile 4 (> $56,903) 423 24.0 1.13 0.64 1.99 0.6797 1.05 0.53 2.07 0.8913 
Smoking                     
   Never 255 14.4 1.00 reference   1.00 reference   
   Past/Current 305 17.3 2.42 1.17 5.01 0.0177 2.21 1.06 4.62 0.0353 
   Unknown 1205 68.3 1.74 0.89 3.38 0.105 1.65 0.82 3.31 0.1576 
Insulin 349 19.8 1.46 0.94 2.28 0.0962 1.54 0.96 2.46 0.0707 
Health Severity Risk Score                     
   Quartile 1 (≤ 1.0 ) 451 25.6 1.00 reference   1.00 reference   
   Quartile 2 (1.0 - 1.4) 447 25.3 1.64 0.86 3.14 0.1361 1.16 0.58 2.35 0.6729 
   Quartile 3 (1.4 - 2.1) 449 25.4 1.95 1.06 3.60 0.032 1.14 0.57 2.29 0.7075 
   Quartile 4 (≥ 2.1 ) 418 23.7 3.65 2.06 6.46 <.0001 2.05 1.04 4.03 0.038 
Quality of Care Measures (2003)                     
   All 3 QOCM*  263 14.9 0.47 0.23 0.96 0.0377 0.39 0.19 0.81 0.0117 
 
* 2 A1C measurements, 1 microalbuminuria test, and 1 lipid test in 2003 
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4.5.3 Stroke 
During the six-year observation period, 152 diabetics submitted at least one medical claim for 
stroke.  Stroke was the second most frequent complication in the cohort (8.7%), with a mean 
time-to-complication of 33.1 months. The risk of submitting a medical claim for stroke was 0.63 
(HR 0.63, 95% CI [0.38 – 1.07], p = 0.0891) for diabetics receiving all three QOCM in the 
baseline year compared to diabetics who received less than all three QOCM in the baseline year.   
Certain covariates were more likely to be associated with having a medical claim for 
stroke as a complication of diabetes in the multivariate model (see Table 8).  Males (HR 0.77, 
95% CI [0.50 - 1.21], p = 0.261) were less likely to have strokes than females, but the difference 
was not significant. The hazard rate for Hispanics was lower relative to blacks and whites (HR 
0.55, 95% CI [0.28 - 1.08], p = 0.083) with borderline significance.  Similarly, Karter (2008) 
reported a lower hazard rate for Latinos (HR 0.72, 95% CI [0.59 - 0.88], p < 0.002 ) relative to 
whites and blacks.  Increasing age was significantly associated with increased risk for stroke for 
52 to 56 year olds (HR 2.95, 95% CI [1.69 - 5.15], p = 0.0001).  Smoking, either in the past or 
during the study, also was significantly associated with increased risk of stroke (HR 2.21, 95% 
CI [1.06 - 4.62], p = 0.00353). Increasing age and smoking are known risk factors for stroke 
among diabetics (Rodbard et al., 2007).  A health severity risk score of 2.1 or higher was 
associated with a significantly increased risk for stroke compared to those with lower scores (HR 
2.04, 95% CI [1.18 - 3.04], p = 0.011).  Consistent with observations reported  by Libby and 
colleagues (2005), neither insulin use nor smoking was significantly associated with risk of 
stroke.  
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Table 8.  Multivariate Associations with Stroke (2004-2009) 
Characteristic 
All 
(N = 1751) 
Bivariate 
Multivariate (demographics, 
lifestyle, QOC, and HSRS) 
Age n % HR 95% CI p-value HR 95% CI p-value 
   18 - 45 517 29.5 1.00 reference   1.00 reference   
   46 - 51 457 26.1 1.80 1.02 3.16 0.042 1.53 0.85 2.75 0.1545 
   52 - 56 453 25.9 3.67 2.19 6.16 <.0001 2.95 1.69 5.15 0.0001 
   57- 64 324 18.5 6.21 3.60 10.72 <.0001 4.65 2.57 8.44 <0.0001 
Gender                     
    Male 1453 83.0 0.71 0.49 1.05 0.0875 0.77 0.50 1.21 0.2609 
Race                     
    White 1210 69.1 1.00 reference   1.00 reference   
    Black 340 19.4 0.78 0.51 1.20 0.2621 0.81 0.52 1.25 0.3304 
    Hispanic 162 9.3 0.51 0.26 1.00 0.0508 0.55 0.28 1.08 0.0833 
    Other 39 2.2 0.31 0.04 2.18 0.236 0.23 0.03 1.66 0.1452 
Marital Status                     
    Married 1295 74.0 0.98 0.68 1.41 0.9231 0.88 0.60 1.31 0.543 
Compensation                     
    Hourly 1332 76.1 1.13 0.77 1.67 0.5231 1.27 0.81 1.98 0.2988 
Wage                     
    Quartile 1 (< $35,423) 474 27.1 1.00 reference   1.00 reference   
    Quartile 2 ($35,424 - $44,743) 427 24.4 0.81 0.51 1.31 0.3925 0.85 0.52 1.41 0.5351 
    Quartile 3 ($44,744 - $56,903) 432 24.7 0.93 0.59 1.45 0.7364 1.15 0.70 1.89 0.5907 
    Quartile 4 (> $56,903) 418 23.9 1.12 0.72 1.73 0.6123 1.28 0.74 2.21 0.3713 
Smoking                     
    Never 253 14.4 1.00 reference   1.00 reference   
    Past/Current 301 17.2 1.61 0.91 2.83 0.0997 1.35 0.76 2.38 0.3043 
    Unknown 1197 68.4 1.46 0.90 2.40 0.1289 1.39 0.83 2.32 0.2171 
Insulin 354 20.2 1.06 0.71 1.57 0.7779 1.04 0.69 1.57 0.8559 
Health Severity Risk Score                     
    Quartile 1 (≤ 1.0 ) 447 25.5 1.00 reference   1.00 reference   
    Quartile 2 (1.0 - 1.4) 448 25.6 1.29 0.75 2.22 0.366 0.94 0.52 1.69 0.8221 
    Quartile 3 (1.4 - 2.1) 439 25.1 2.26 1.41 3.63 0.0007 1.46 0.85 2.51 0.1704 
    Quartile 4 (≥ 2.1 ) 417 23.8 3.30 2.08 5.23 <.0001 2.04 1.18 3.52 0.0105 
Quality of Care Measures (2003)                     
    All 3 QOCM*  263 15.0 0.63 0.37 1.05 0.0785 0.63 0.38 1.07 0.0891 
 
* 2 A1C measurements, 1 microalbuminuria test, and 1 lipid test in 2003 
4.5.4 Renal disease (RD) 
During the six-year observation period, 4.9% (n = 86) of the cohort submitted at least one 
medical claim for RD, with a mean time-to-complication of 38.1 months. This group had the 
longest time-to-complication during the six years of observation.  The hazard rate was lower for 
diabetics who received all three QOCM in the baseline year (HR 0.48, 95% CI [0.24 - 0.95], p = 
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0.0339) compared to diabetics who received less than all three QOCM.  The difference between 
the two groups is statistically significant. 
Other covariates were more likely to be associated with medical claims for RD as a 
complication of diabetes in the multivariate model (see Table 9).  There was no statistical 
association observed in the bivariate and multivariate models between males (p = 0.8612) and 
females (p = 0.5447).  Increased hazard rates were associated with increasing age; hazard rates 
were 2.71 for 52 to 56 year olds (95% CI [1.31 - 5.62], p = 0.0073) and 4.19 for 57 to 64 year 
olds (95% CI [1.89 - 9.26], p = 0.0004).  Relative to whites, blacks (HR 1.77, 95% CI [1.06 - 
2.97], p = 0.0295) had a statistically significant higher risk.  A health severity risk score of 2.1 or 
greater was associated with a higher hazard rate than those with lower scores (HR 2.16, 95% CI 
[1.06 - 4.41], p = 0.0349), and insulin use was associated with a significantly increased risk of 
RD (p = 0.0001).   
 
Table 9.  Multivariate Associations with RD (2004-2009) 
Characteristic 
All 
(N = 1785) 
Bivariate 
Multivariate (demographics, 
lifestyle, QOCM, and 
HSRS) 
Age 
n % HR 95% CI 
p-
value HR 95% CI 
p-
value 
   18 - 45 521 29.2 1.00 reference   1.00 reference   
   46 - 51 467 26.2 1.75 0.86 3.55 0.1234 1.70 0.80 3.58 0.1657 
   52 - 56 467 26.2 3.15 1.62 6.11 0.0007 2.71 1.31 5.62 0.0073 
   57- 64 330 18.5 5.19 2.54 10.59 <.0001 4.19 1.89 9.26 0.0004 
Gender                     
    Male 1486 83.2 0.95 0.55 1.66 0.8612 1.22 0.65 2.29 0.5447 
Race                     
    White 1234 69.1 1.00 reference   1.00 reference   
    Black 344 19.3 1.47 0.90 2.42 0.1268 1.77 1.06 2.97 0.0295 
    Hispanic 166 9.3 1.39 0.73 2.66 0.3197 1.60 0.82 3.11 0.1693 
    Other 41 2.3 0.00 0.00 . 0.9798 0.00 0.00 . 0.9791 
Marital Status                     
    Married 1324 74.2 1.44 0.84 2.48 0.1885 1.27 0.71 2.27 0.4209 
Compensation                     
    Hourly 1354 75.9 0.86 0.53 1.38 0.526 0.76 0.44 1.33 0.3395 
Wage                     
    Quartile 1 (< $35,423) 484 27.1 1.00 reference   1.00 reference   
 69 
Table 9 (continued) 
 
    Quartile 2 ($35,424 - $44,743) 434 24.3 1.08 0.59 1.99 0.8059 0.99 0.52 1.87 0.9687 
    Quartile 3 ($44,744 - $56,903) 442 24.8 1.09 0.60 1.96 0.7834 1.19 0.62 2.28 0.6063 
    Quartile 4 (> $56,903) 425 23.8 0.98 0.53 1.83 0.9541 0.84 0.40 1.76 0.6515 
Smoking                 
    Never 255 14.3 1.00 reference   1.00 reference   
    Past/Current 310 17.4 1.98 0.85 4.58 0.1123 2.01 0.86 4.69 0.1074 
    Unknown 1220 68.3 2.25 1.07 4.72 0.0316 2.22 1.03 4.77 0.0411 
Insulin 357 20.0 2.69 1.74 4.15 <.0001 2.52 1.58 4.03 0.0001 
Health Severity Risk Score                     
    Quartile 1 (≤ 1.0 ) 450 25.2 1.00 reference   1.00 reference   
    Quartile 2 (1.0 - 1.4) 448 25.1 1.38 0.68 2.81 0.3766 0.95 0.44 2.05 0.8966 
    Quartile 3 (1.4 - 2.1) 451 25.3 1.38 0.70 2.75 0.3533 0.82 0.38 1.79 0.6243 
    Quartile 4 (≥ 2.1 ) 436 24.4 4.01 2.21 7.28 <.0001 2.16 1.06 4.41 0.0349 
Quality of Care Measures (2003)                     
    All 3 QOCM*  266 14.9 0.71 0.37 1.38 0.3119 0.48 0.24 0.95 0.0339 
 
* 2 A1C measurements, 1 microalbuminuria test, and 1 lipid test in 2003 
 
4.5.5 Any of the four complications 
During the six-year observation period, a total of 366 diabetics (24%, N = 1,797) had medical 
claims for at least one of the four complications with a mean time-to-complication of 29.1 
months (see Table 10). The hazard rate for submitting a medical claim for any of the four 
complications was significantly lower for those receiving all three QOCM (HR 0.66, 95% CI 
[0.48 - 0.91], p = 0.0101).   
Increasing age was significantly associated with a higher risk for complications.  Health 
severity risk scores of 2.1 or higher were significantly associated with higher hazard rates than 
lower scores (HR 1.91, 95% CI [1.36 - 2.68], p = 0.0002).  There is also evidence that smoking, 
independent of the other factors, contributed to risk (HR 1.44, 95% CI [1.01 – 2.07], p = 0.0468).  
Differences in all other covariates were not statistically significant. 
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Table 10.  Multivariate Associations with Any of the Four Complications (2004-2009) 
Characteristic 
All 
(N = 1526) 
Bivariate 
Multivariate (demographics, 
lifestyle, QOCM, and HSRS) 
Age n % HR 95% CI p-value HR 95% CI p-value 
    18 - 45 487 31.9 1.00 reference   1.00 reference   
    46 - 51 407 26.7 2.04 1.50 2.79 <.0001 1.88 1.36 2.61 0.0001 
    52 - 56 370 24.2 2.43 1.78 3.32 <.0001 2.06 1.47 2.89 <.0001 
    57- 64 262 17.2 3.89 2.80 5.41 <.0001 3.09 2.15 4.46 <.0001 
Gender                     
    Male 1262 82.7 1.09 0.82 1.44 0.5437 1.18 0.87 1.61 0.2867 
Race                     
    White 1036 67.9 1.00 reference   reference     
    Black 301 19.7 1.00 0.78 1.30 0.9791 1.05 0.80 1.36 0.7457 
    Hispanic 150 9.8 0.80 0.56 1.16 0.2411 0.86 0.60 1.25 0.4369 
    Other 39 2.6 0.90 0.42 1.90 0.7715 0.83 0.39 1.77 0.6282 
Marital Status                     
    Married 1112 72.9 1.12 0.89 1.43 0.3346 0.99 0.77 1.28 0.9475 
Compensation                     
    Hourly 1149 75.3 1.09 0.85 1.39 0.4959 1.09 0.82 1.44 0.5436 
Wage                     
    Quartile 1 (< $35,423) 410 26.9 1.00 reference   1.00 reference   
    Quartile 2 ($35,424 - $44,743) 373 24.4 1.10 0.81 1.48 0.5484 1.00 0.73 1.36 0.9988 
    Quartile 3 ($44,744 - $56,903) 377 24.7 1.04 0.78 1.39 0.7946 0.96 0.70 1.32 0.8029 
    Quartile 4 (> $56,903) 366 24.0 1.13 0.84 1.51 0.43 0.98 0.69 1.39 0.9029 
Smoking                     
    Never 228 14.9 1.00 reference   1.00 reference   
    Past/Current 255 16.7 1.55 1.08 2.21 0.0173 1.44 1.01 2.07 0.0468 
    Unknown 1043 68.3 1.31 0.97 1.78 0.0817 1.30 0.94 1.79 0.1118 
Insulin 300 19.7 1.16 0.90 1.49 0.2476 1.20 0.92 1.55 0.1797 
Health Severity Risk Score                     
    Quartile 1 (≤1.0 ) 435 28.5 1.00 reference   1.00 reference   
    Quartile 2 (1.0 - 1.4) 423 27.7 1.53 1.13 2.08 0.0068 1.20 0.87 1.66 0.2731 
    Quartile 3 (1.4 - 2.1) 387 25.4 1.93 1.44 2.60 <.0001 1.38 0.99 1.91 0.0541 
    Quartile 4 (≥ 2.1 ) 281 18.4 2.70 2.00 3.66 <.0001 1.91 1.36 2.68 0.0002 
Quality of Care Measures (2003)                     
    All 3 QOCM *  232 15.2 0.72 0.53 0.99 0.041 0.66 0.48 0.91 0.0101 
 
* 2 A1c measurements, 1 microalbuminuria test, and 1 lipid test in 2003 
 
 
4.6 TIME TREND ANALYSES 
The Kaplan-Meier estimates of cumulative hazards for all complications indicate that differences 
between the two quality of diabetes care groups began to develop early in the observation period 
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(see Figure 2 and Table 11).  The cumulative hazards for CAD begin to diverge at three months, 
converge at 32 months and then diverge again at 37 months, continuing through the remainder of 
the observation period.  For HF, the curves separate soon after the baseline period at four months 
and show increasing benefits associated with quality of diabetes care continuing through the end 
of the observation period.  For Stroke, the cumulative hazard function diverges at four months 
and continues to demonstrate benefits through the six-year observation period.  For RD, the 
cumulative hazard function diverges at 27 months, narrows at 61 months and then diverges for 
the remainder of the observation period.  For any of the four complications, the treatment groups 
begin to diverge at two months with a narrowing at 31 months.  However, the divergence persists 
through the observation period, showing the benefits associated with higher quality of diabetes 
care.   
Adjusted models indicate that diabetics who received all three QOCM experienced a 
significantly lower risk for HF (HR 0.39, 95% CI [0.19 - 0.81], p = 0.0117).  Based on the 
adjusted multivariate analysis, diabetics who received all three QOCM also experienced a 
significantly delayed onset of RD (HR 0.48, 95% CI [0.24 - 0.95], p = 0.0339); in fact, diabetics 
who received all three QOCM experienced delayed onset for any of the four complications 
compared to the other group (HR 0.66, 95% CI [0.48 - 0.91], p = 0.0101).  Hazard rates for the 
cohort are presented in Table 11. 
 
Table 11.  Cox Proportional Hazard Regression Model for the Effect of Receiving All Three QOCM* on 
Complications (2003) 
 
  
Complication 
Unadjusted HR Adjusted HR** 
HR 95% CI p-value HR 95% CI p-value 
CAD (n = 1580) 0.76 0.53 1.10 0.1424 0.70 0.49 1.02 0.0635 
HF  (n = 1765) 0.47 0.23 0.96 0.0377 0.39 0.19 0.81 0.0117 
Stroke (n = 1751) 0.63 0.37 1.05 0.0785 0.63 0.38 1.07 0.0891 
RD (n = 1785) 0.71 0.37 1.38 0.3119 0.48 0.24 0.95 0.0339 
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Any of the 4 (n = 1526) 0.72 0.53 0.99 0.041 0.66 0.48 0.91 0.0101 
 
  * 2 A1C measurements, 1 microalbuminuria test, and 1 lipid test in 2003 
** Demographics, modifiable risks, clinical measures of risk 
 
Kaplan-Meier estimates of cumulative hazard ratios for complications are presented in 
Figure 2 (a-e).  All hazard ratios were adjusted based on demographic characteristics, lifestyle 
factors, health severity risk scores and disease severity based on insulin use.   
 
 
(a) CAD (n = 1,580, HR  .70, 95% [CI .49 - 1.02], p = 0.0635) 
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(b) HF (n = 1,765, HR 0.39, 95% CI [0.19 - 0.81], p = 0.0117) 
 
 
(c) Stroke (n = 1,751, HR 0.63, 95% CI [0.38 – 1.07], p = 0.0891) 
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(d) RD (n = 1,785, HR 0.48, 95% CI [0.24 – 0.95], p = 0.0339) 
 
 
(e) Any of the four complications (n = x, HR 0.66, 95% CI [0.48 – 0.92], p = 0.0101) 
Figure 2 (a-e).  Kaplan-Meier estimates of cumulative hazard ratios for all complications. 
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4.6.1 Time trend subgroup analysis for hourly employees  
The analysis was repeated after stratifying the data by hourly employee status.  The Kaplan-
Meier estimates of cumulative hazards for all complications indicate that the differences between 
the two quality of diabetes care groups began to develop early in the observation period (see 
Figure 3).  The cumulative hazard functions for CAD begin to diverge at six months, converge at 
27 months and then diverge again at 42 months, showing benefits through the remainder of the 
observation period.  For HF, the curves separate at nine months and show increasing benefits 
associated with quality of diabetes care continuing through the end of the observation period.  
For Stroke, the cumulative hazard functions diverge soon after the end of the baseline period, 
narrow from 12 to 18 months, and then continue to diverge for the remainder of the six-year 
observation period.  For RD, the cumulative hazard functions diverge at nine months, narrow at 
21 months, then diverge until 66 months and converge again for the remainder with the of the 
observation period.  For any of the four complications, the treatment groups begin to diverge at 
six months with a narrowing at 26 months, and then diverge again at 30 months through the end 
of the observation period, demonstrating the benefits associated with receiving all three QOCM.   
Adjusted models for HF identify that hourly employees who received all three QOCM 
experienced significantly lower risk for HF (HR 0.432, 95% CI [0.20 - 0.95], p = 0.0374).  Based 
on the adjusted multivariate analysis, hourly employees who received all three QOCM 
experienced delayed onset of RD (HR 0.42, 95% CI [0.18 - 1.01], p = 0.0527); in fact, hourly 
employees who received all three QOCM experienced delayed onset for any of the four 
complications (HR 0.719, 95% CI [0.499 - 1.036], p = 0.0768).  Hazard rates for hourly 
employees are presented in Figure 3 (a-e).  
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(a) CAD (n = 1,182, HR .075, 95% CI [0.49 - 1.14], p = 0.1751) 
 
 
(b) HF (n = 1,335, HR 0.432, 95% CI [0.20 – 0.95], p = 0.0374) 
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(c) Stroke (n = 1,332, HR 0.68, 95% CI [0.37 – 1.25], p = 0.2116) 
 
 
(d) RD (n = 1,354, HR 0.42, 95% CI [0.18 = 1.01], p = 0.0527) 
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(e) Any of the four complications (n = 1,149, HR 0.719, 95% CI [0.499 – 1.036], p = 0.0768) 
Figure 3 (a-e).  Time trend subgroup analysis for hourly employees. 
 
4.6.2 Time trend subgroup analysis for salaried employees 
The analysis was repeated after stratifying the data by salaried employee status.  The Kaplan-
Meier estimates of cumulative hazards for all complications indicate that differences between the 
two quality of diabetes care groups began to develop early in the observation period (see Figure 
4).  The cumulative hazard functions for CAD begin to diverge at two months, converge at 19 
months and then diverge again at 32 months, showing benefits through the remainder of the 
observation period.  For HF, the curves separate at five months, soon after the baseline period 
ends, and show increasing benefits associated with quality of diabetes care through the 
observation period.  For Stroke, the cumulative hazard functions diverge at eight months and 
narrow at 30 months, continuing to demonstrate benefits through the six-year observation period.  
For renal disease, the cumulative hazard functions are balanced between the two groups, with a 
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divergence at 64 months.  For any of the four complications, the treatment groups begin to 
diverge at four months and narrow at 27 months.  However, the divergence persists through the 
end of the observation period, demonstrating the benefits associated with receiving all three 
QOCM.   
Salaried employees who received all three QOCM in the adjusted multivariate analysis 
experienced a statistically significant lower risk for developing HF (HR 0.92, 95% CI [0.010 - 
0.841], p = 0.0346).  Adjusted models show that salaried employees who received all three 
QOCM also approached a statistically significant delay in the onset of RD (HR 0.27, 95% CI 
[0.07 - 1.00], p = 0.0501).  Similarly, based on the adjusted multivariate analysis, salaried 
employees who received all three QOCM experienced delayed onset for any of the four 
complications (HR 0.422, 95% CI [0.216 - 0.846], p = 0.0118).  Hazard rates for salaried 
employees are presented in Figure 4 (a-e).  
 
 
(a) CAD (n = 398, HR 0.48, 95% CI [0.21 – 1.10], p = 0.0841) 
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(b) HF (n = 430, HR 0.092, 95% CI [0.010 – 0.841], p = 0.0346) 
 
 
(c) Stroke (n = 419, HR 0.42, 95% CI [0.14 – 1.30], p = 0.1317) 
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(d) RD (n = 431, HR 0.27, 95% CI [0.07 – 1.00], p = 0.0501) 
 
 
(e) Any of the four complications (n = 377, HR = 0.422, 95% CI [0.216 – 0.826], p = 0.0118) 
Figure 4 (a-e).  Time trend subgroup analysis for salaried employees. 
 
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
1 4 7 1
0
1
3
1
6
1
9
2
2
2
5
2
8
3
1
3
4
3
7
4
0
4
3
4
6
4
9
5
2
5
5
5
8
6
1
6
4
6
7
7
0
7
3
RD
<3 QOCM All 3 QOCM
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
0 3 6 9 1
2
1
5
1
8
2
1
2
4
2
7
3
0
3
3
3
6
3
9
4
2
4
5
4
8
5
1
5
4
5
7
6
0
6
3
6
6
6
9
7
2
Any of the Four Complications
<3 QOCM All 3 QOCM
 82 
4.6.3 Time trend subgroup analysis for males 
The analysis was repeated after stratifying the data by male gender.  The Kaplan-Meier 
cumulative hazard estimates for all complications indicate that differences between the two 
quality of diabetes care groups began to develop early in the observation period (see Figure 5).  
The cumulative hazards for CAD begin to diverge at two months, converge at 32 months and 
then diverge again at 37 months, showing benefits through the remainder of the observation 
period.  For HF, the curves separate at 10 months and show increasing benefits associated with 
quality of diabetes care continuing through the observation period.  For Stroke, the cumulative 
hazard functions diverge at eight months and continue to demonstrate benefits through the six-
year observation period. For RD, the cumulative hazard functions diverge at ten months, narrow 
at 23 months and then diverge at 28 months for the remainder of the observation period.  For any 
of the four complications, the treatment groups begin to diverge at two months and continue to 
widen for the remainder of the observation period, demonstrating the benefits associated with 
receiving all three QOCM.   
Based on the adjusted multivariate analysis, male diabetics who received all three QOCM 
experienced lower risk for developing CAD (HR 0.632, 95% CI [0.420 - 0.951], p = 0.0276).  
Males who received all three QOCM also experienced delayed onset of HF (HR 0.273, 95% CI 
[0.109 - 0.682], p = 0.0055) and RD (HR 0.371, 95% CI [0.166-0.831], p=0.0160).  In fact, the 
adjusted multivariate analysis indicates that males who received all three QOCM experienced 
delayed onset for any of the four complications (HR 0.592, 95% CI [0.414 - 0.846], p = 0.0040).  
Hazard rates for male employees are presented in Figure 5 (a-e).  
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(a) CAD (n = 1,305, HR 0.632, 95% CI [0.420 – 0.951], p = 0.0276) 
 
 
(b) HF (n = 1,467, HR 0.273, 95% CI [1.09 – 0.682], p = 0.0055) 
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(c) Stroke (n = 1,453, HR 0.581, 95% CI [0.318 – 1.063], p = 0.0781) 
 
 
(d) RD (n = 1,486, HR 0.371, 95% CI [0.166 – 0.831], p = 0.0160) 
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(e) Any of the four complications (n = 1,262, HR 0.592, 95% CI [0.414 – 0.846], p = 0.0040) 
Figure 5 (a-e).  Time trend subgroup analysis for males. 
4.6.4 Time trend subgroup analysis for females 
The stratum of women shows no evidence of benefit or harm associated with QOCM and CAD, 
HF, Stroke, RD or for any of the four complications. 
4.6.5 Time trend subgroup analysis for insulin users 
The analysis was repeated after stratifying the data based on insulin use.  The Kaplan-Meier 
cumulative hazard estimates for all complications indicate that differences between the two 
quality of diabetes care groups began to develop early in the observation period (see Figure 6).  
The cumulative hazard functions for CAD begin to diverge at three months, converge at 32 
months and then diverge again at 37 months, showing benefits through the remainder of the 
observation period.  For HF, the curves separate soon after the baseline period ends, at four 
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months, and demonstrate increasing benefits associated with higher quality diabetes care 
continuing through the observation period.  For Stroke, the cumulative hazard functions diverge 
at four months and continue to demonstrate benefits through the six-year observation period.  For 
RD, the cumulative hazard functions diverge at 27 months, narrow at 61 months, and then 
diverge for the remainder of the observation period.  For any of the four complications, the 
treatment groups begin to diverge at two months with a narrowing at 31 months.  However, the 
divergence persists through the observation period, demonstrating the benefits associated with 
receiving all three QOCM.  Based on the adjusted multivariate analysis, insulin users who 
received all three QOCM were at lower risk for developing HF (HR 0.190, 95% CI 0.041 – 
0.871, p = 0.0325).  Hazard rates for insulin users are presented in Figure 6 (a-e).   
 
 
 
(a) CAD (n = 311, HR 0.898, 95% CI [0.4571 - 1.768], p = 0.7566) 
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(b) HF (n = 349, HR 0.190, 95% CI [0.041 – 0.871], p = 0.0325) 
 
 
(c) Stroke (n = 354, HR 0.738, 95% CI [0.264-2.063], p = 0.5619) 
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(d) RD (n = 357, HR 0.483, 95% CI [0.18 – 1.291], p = 0.1468) 
 
 
(e) Any of the four complications (n = 300, HR = 0.644, 95% CI [0.349 – 1.186], p = 0.1578) 
 
Figure 6 (a-e).  Time trend subgroup analysis for insulin users. 
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4.6.6 Time trend subgroup analysis for insulin non-users 
The analysis was repeated after stratifying the data for insulin non-users. The Kaplan-Meier 
cumulative hazard estimates for all complications indicate that differences between the two 
quality of diabetes care groups began to develop early in the observation period (see Figure 7).  
The cumulative hazards for CAD begin to diverge at three months, converge at 32 months and 
then diverge again at 37 months, showing benefits through the remainder of the observation 
period.  For HF, the curves separate soon after baseline period at four months, and show 
increasing benefits associated with quality of diabetes care continuing through the end of the 
observation period.  For Stroke, the cumulative hazard functions diverge at four months and 
continue to demonstrate benefits through the six-year observation period.  For RD, the 
cumulative hazard functions diverge at 27 months, narrow at 61 months and then diverge for the 
remainder of the observation period.  For any of the four complications, the treatment groups 
begin to diverge at two months with a narrowing at 31 months.  
Based on the adjusted multivariate analysis, insulin non-users who received all three 
QOCM experienced a statistically significant lower risk for developing CAD (HR 0.604, 95% CI 
[0.375 - 0.972], p = 0.0377).  Adjusted models identify that insulin non-users who received all 
three QOCM also experienced delayed onset of HF (HR 0.445, 95% CI [0.192 - 1.032], p = 
0.0593) as well as statistically significant delayed onset for any one of the four complications 
(HR 0.605, 95% CI [0.408 - 0.896], p = 0.0122).  Hazard rates for insulin non-users are 
presented in Figure 7 (a-e).   
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(a) CAD (n = 1,269, HR 0.604, 95% CI [0.375 – 0.972], p = 0.0377) 
 
 
(b) HF (n = 1,416, HR 0.445, 95% CI [0.192 -1.032], p = 0.0593) 
 
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
1 4 7 1
0
1
3
1
6
1
9
2
2
2
5
2
8
3
1
3
4
3
7
4
0
4
3
4
6
4
9
5
2
5
5
5
8
6
1
6
4
6
7
7
0
7
3
CAD
<3 QOCM All 3 QOCM
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
1 4 7 1
0
1
3
1
6
1
9
2
2
2
5
2
8
3
1
3
4
3
7
4
0
4
3
4
6
4
9
5
2
5
5
5
8
6
1
6
4
6
7
7
0
7
3
HF
<3 QOCM All 3 QOCM
 91 
 
(c) Stroke (n = 1,397, HR 0.595, 95% CI [0.319 – 1.111], p = 0.1033) 
 
 
(d) RD (n = 1,428, HR 0.411, 95% CI [0.147 – 1.148], p = 0.0898) 
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(e) Any of  the four complications (n = 1,226, HR 0.605, 95% CI [0.408 – 0.896], p = 0.0122) 
Figure 7 (a-e).  Time trend subgroup analyses for non-insulin users. 
4.7 SENSITIVITY ANALYSES 
The sensitivity analyses based on correlation analysis and Kappa statistics for two years (2003 
and 2004) of continuous QOCM were consistent (see Tables 12 and 13).  Even though the 
concordance between the two models as evidenced by the Kappa statistics and correlation 
analyses are not as strong as anticipated, the trends are the same and the  point estimates and 
95% CI’s are similar.  The hazard rates for QOCM in 2003 and 2004 are all in the same direction 
but not significant (see Table 14).  A comparison of these results to those for 2003 only (see 
Table 11) supports using the signal year of 2003 as the baseline for the analysis.  
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Table 12.  Correlation Coefficients for Number of QOCM 
Years 
Number 
of 
QOCM 
Correlation 
Coefficient 
2003 and 2004 4 0.47 
2003 and 2004 3 0.44 
 
Table 13.  Kappa Statistics for Two Years of Continuous QOCM 
QOCM 
2003 2004 
Received in 2004 
(from those who 
received in 2003) 
% 
Agreement 
Kappa* 
n % n % n % 
≥ 1 Lipid 985 62.3 1076 68.1 781 79.3 68.4 0.30 
≥ 1 A1C 1075 68.0 1148 72.6 924 86.0 76.3 0.43 
≥ 2 A1C 693 43.8 711 45.0 458 66.1 69.1 0.37 
≥ 1 Microalbuminuria 380 24.0 468 29.6 222 58.4 74.4 0.35 
> All 3 236 14.9 300 19 112 47.5 80.2 0.30 
* Kappa agreement:   < 0 = less than chance; 0 .01 - 0.20 = slight; 0.21 – 0.40 = fair; 0.41 – 0.60 = moderate; 0.61-
0.80 = substantial; 0.81 – 0.99 = almost perfect 
 
Table 14. Cox Proportional Hazards Regression Model of the Effect of Receiving all Three QOCM* in 2003 and 
2004 on Complications 
 
  
Complication 
Unadjusted HR Adjusted HR** 
HR 95% CI p-value HR 95% CI p-value 
CAD (n = 1301) 0.71 0.38 1.35 0.30 0.64 0.34 1.23 0.1799 
HF  (n = 1497) 0.35 0.09 1.44 0.148 0.30 0.07 1.24 0.096 
Stroke (n = 1486) 0.56 0.23 1.37 0.201 0.56 0.23 1.38 0.21 
RD (n = 1523) 0.77 0.23 2.10 0.603 0.54 0.19 1.53 0.23 
Any of the 4 (n = 1285) 0.73 0.44 1.20 0.214 0.65 0.39 1.09 0.104 
  * 2 A1C measurements, 1 microalbuminuria test, and 1 lipid test in 2003 
** Demographics, modifiable risks, clinical measures of risk 
 
 94 
5.0  DISCUSSION 
This study compared two groups of diabetics to assess how differences in quality of diabetes care 
affected the onset of four complications associated with diabetes.  Significant differences in 
time-to-complication were observed between the two groups for three of the four complications 
(CAD, HF and RD) and for any of the four complications when viewed in aggregate.  The 
estimated hazard ratios and 95% confidence intervals for time-to-complication in the models 
(which were adjusted for demographics, lifestyle factors and health severity risk scores) for those 
who received all three QOCM were:   CAD (HR 0.95, 95% CI [0.91 - 0.98], p = 0.0019),  
HF (HR 0.39, 95% CI [0.19 - 0.81], p = 0.0117), Stroke (HR 0.95, 95% CI [0.95 – 1.00], p = 
0.0382), RD (HR 0.48, 95% CI [0.24 - 0.95], p = 0.0339) and any of the four complications (HR 
0.66, 95% CI [0.48 - 0.91], p = 0.0101).  There are many studies that assess whether 
interventions at the provider level improve processes of care and intermediate outcomes, but the 
effect of such process improvements on complications remains less clear because such outcomes 
are rarely assessed (Renders et al., 2001).  This study estimates the impact of QOCM on 
reducing the risk of complications by analyzing data across multiple physician groups 
administering diabetes care within the same health insurance plan structure.  
The unadjusted prevalence of diabetes in the study population was 19.7% - more than 
twice the 8.7% national rate reported by the CDC for adults over the age of 20 (Centers for 
Disease Control and Prevention, 2003).  The case definition in our study may have overestimated 
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diabetes prevalence since anyone with a prescription for a diabetes drug was classified as a 
diabetic, even if they were not assigned an ICD-9 code for T1DM or T2DM.  In order to classify 
cases correctly, more accurate coding by physicians is required, particularly in cases where 
T2DM is treated with insulin, which previously may have been coded as T1DM.  In addition, the 
CDC prevalence rate is based on self-reports, and may underestimate the prevalence of diabetes 
in the total population.   
Despite sample size differences, there were no statistically significant differences 
between the two study groups at baseline based on demographic, SES or modifiable risk 
variables, with the exception of insulin prescriptions in the baseline year.  On a percentage basis, 
more diabetics in the group that received all three QOCM used insulin (27.7 %, n = 74) 
compared to the group that received less than three QOCM (18.8 %, n = 287), which was a 
statistically significant difference (p = 0.0007).  Health severity risk scores were also 
significantly different between the two groups (p = 0.0429).  Diabetics in the group receiving 
less than three QOCM were evenly distributed across the quartiles for health severity risk score, 
whereas those in the group receiving all three QOCM had higher risk scores across Quartiles 2 
through 4.  In addition to co-morbidities, health severity risk scores include age and gender; as a 
result, the differences between the two study groups may have been underestimated in the 
categories of age, gender and insulin use.   
In the multivariate analyses (which were adjusted for all covariates), diabetics with 
increasing health severity risk scores who received all three QOCM experienced lower hazard 
rates for complications compared to those who received less than three QOCM; this held true 
across all outcomes and strata.  The differences were not necessarily associated with access to 
care, since all study participants were enrolled in the same health insurance plan; however, 
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quality of care may have been affected by provider education, provider incentives or patient 
education.   
Certain characteristics were more likely to be associated with developing CAD as a 
complication of diabetes in the multivariate model (see Table 6).  Although males (HR 1.72, 
95% CI [1.15 - 2.56], p = 0.008) were significantly more likely to develop CAD than females, 
the rates among all races did not differ significantly.  Increasing age was also associated with 
increased risk for CAD, especially for those aged 46 to 51 years (HR 1.81, 95% CI [1.24 - 2.54], 
p=0.002).  Smoking, either in the past or during the study, also produced a borderline significant 
increase in the hazard rate for CAD (HR 1.47, 95% CI [0.97 - 2.21], p = 0.0676).  These findings 
related to increasing age and smoking are consistent with those in national surveillance reports 
(Cowie et al., 2003) and population-based studies of CAD and diabetes (Rodbard et al., 2007).   
As shown in Tables 11 and 12, the sensitivity analyses for two years of 
continuous optimal care based on correlation analyses and Kappa statistics were consistent. 
Trends for two years and one year of optimal care (see Table 12) were the same, with similar 
point estimates and 95% CIs.  The hazard rates were all in the same direction, but not significant 
(see Table 13). Even though the concordance between the two models was not as strong as 
anticipated, the results supported using the signal year of 2003 as the baseline for the analysis.  
5.1 STRENGTHS AND LIMITATIONS 
This analysis suggests that quality of diabetes care, as measured by adherence to ADA guidelines 
for A1C, microalbuminuria and lipid tests, is an independent predictor of diabetes complications 
- regardless of access to care and other risk factors.  Although disease management strategies 
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have been employed, and improvements in diabetes care have been reported over time in the US 
(Saaddine et al., 2006; Saaddine et al., 2002), a widely recognized gap still exists between the 
quality of care diabetics should receive and the care they do receive.  Closing this gap remains a 
major challenge in the United States.   
This study has several strengths, including a large sample size of diabetics who were 
employed by the same US manufacturer and were enrolled in the same health insurance plan.  
The population was ethnically, socioeconomically and geographically diverse, and processes of 
diabetes care data were derived from medical insurance claims, versus self-reported surveys.  
Smoking data were obtained from occupational health medical records, and financial data from 
company records.  Using the health severity risk score allowed for adjustment of comorbidities 
using data from insured populations, since it could not be assumed that comorbidities would be 
comparable for the uninsured.  Previous studies used the Charlson Index to adjust for 
comorbidities, but it was not as applicable to this study since it uses Medicare and Medicaid 
populations to derive comparisons.  
A second strength of the study is the statistically significant difference in baseline 
characteristics for insulin use and health severity risk scores of the study population.  At baseline 
there is evidence of reverse causality.  Such disparities should predict more care for those 
diabetics who are less healthy at baseline – yet, that was not the case.  This is further evidence 
that the study may have underestimated the benefits of good care 
A third strength of the study is the setting itself.  Random effects are reduced by 
evaluating the quality of care delivered through the same provider networks within the 
employment context.  This a highly advantageous study setting for analyzing associations of 
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quality of healthcare and disease outcomes (Einav, Finkelstein, & Cullen, 2010; Einav, 
Finkelstein, Pascu, & Cullen, Under Review; Einav, Finkelstein, Ryan, Schrimpf, & Cullen). 
Another strength of this study, is the use of personnel, financial and administrative health 
insurance claims data, is also a limitation.  Administrative datasets provide verified SES data for 
sex, age, ethnicity and salary data. The potential for confounding due to misclassification, coding 
errors and omissions are reduced due to the high quality data for  SES measures from the 
manufacturers personnel and financial records.   Additionally, unobserved confounders may 
affect findings when they are not controlled for adequately in the multivariate analysis.  
Moreover, rates of adherence to the NCQA HEDIS quality measures may underreport actual 
quality of care; patients may receive screenings (e.g., dipstick microalbuminuria, finger stick, 
cholesterol) in a healthcare provider’s office or the workplace that are not submitted to the health 
insurance plan for reimbursement, and thus not included in the administrative claims data.  
Another limitation of this study is the inability to fully differentiate between incident and 
prevalent cases in the baseline year, despite data from the two year pre-study period (2001 and 
2002).  This was primarily due to the definition of diabetes cases in this study including a 
combination of office visits, hospitalizations and prescriptions for diabetes medications.  This 
study also demonstrates some of the limitations of using claims datasets.  Using claims data to 
identify diabetes cases as a covariate in statistical models may introduce over and under-
ascertainment and possible bias.   
The study was also limited by a lack of comparison data in order to assess the effect of 
QOCM on intermediate outcomes or medication management.  Previous reports (Selby et al., 
2007) have noted poor concordance between process measures of diabetes care and control of 
intermediate outcomes, suggesting that disease management programs should focus more 
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directly on outcomes to improve their control.  Successful efforts will likely require a better 
understanding of the specific patient and provider factors that affect clinical care and patient 
abilities to manage their diabetes (Selby et al., 2007). 
Another limitation is the length of the baseline period.  Extending the baseline year from 
one year to two years would improve case ascertainment; however, it would shorten the 
observation period and increase the potential for reverse causality (e.g., complications from 
diabetes leading to more care). 
Another important factor is the generalizability of these results.  Based on age, sex, 
tenure and employment status (hourly vs. salary), the 901 employees excluded from the final 
study were not significantly different from those who were included; therefore, it would seem 
most likely that the final study population was representative of the total group.  Generalizability 
is limited to the assessed time frame and to insured populations, who may differ from uninsured 
or publicly-funded patients.3  Also, due to the gap in the literature related to assessing processes 
of care and complications of diabetes, these results are not comparable to other studies based on 
self-reported survey data.   
This study only addresses adherence to three NCQA HEDIS measures for diabetes.  The 
analysis does not assess the HEDIS measures associated with foot examinations and dilated 
retinopathy due to a lack of formal data documenting these procedures.  Also, this analysis 
cannot assert that QOCM are directly related to treatment outcomes.  For example, there is no 
assurance that a specific individual who adheres to the guidelines will achieve goals for 
intermediate outcomes associated with A1C, lipids or blood pressure.  Those with more 
                                                 
3 It is important to note that since the time of these analyses the US health insurance market has changed, 
including the elimination of pre-existing conditions as a barrier to insurance and the introduction of free preventive 
screening for all insured populations. 
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comorbidities may be more likely to satisfy QOCM requirements, but may still not receive 
adequate care.  During the study period, the health insurance provider did not utilize pay for 
performance programs with physician providers to improve compliance with NCQA HEDIS 
measures for diabetes or any other chronic conditions (e.g., asthma, etc.). 
Accreditation organizations such as NCQA emphasize simple process of care measures 
that are easy to document with administrative data (for example, whether A1C was performed).  
Such approaches focus on intermediate outcome levels and their clinical treatments and ignore 
adverse outcomes.  Thus, health plans and disease management programs developed under 
accreditation focus more heavily on improving processes than outcomes of care.  Our findings 
support the need for refinements in disease management that shift the focus toward direct 
measurement and feedback of intermediate outcomes and toward measurement of processes of 
care that are more directly associated with improved outcomes and reducing complications 
(Mangione et al., 2006).  Improving intermediate outcomes is more challenging than altering 
care processes, however.  Process improvements can be more readily applied to entire 
populations with diabetes; but, intermediate outcome control requires identifying patients with 
elevated levels, targeting interventions to their specific needs, and supporting self-management.  
In addition, control of intermediate outcomes requires the active participation of primary care 
physicians who may yet lack sufficient knowledge, decision support resources or time to 
appropriately help patients achieve control (Kerr, Krein, Vijan, Hofer, & Hayward, 2001; 
Mangione et al., 2006).  Future studies should more directly measure which interventions lead to 
appropriate intensification of treatment and monitoring regimens for intermediate outcomes that 
are associated with overall risk or risk reduction for specific complications. 
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Despite these limitations, the study appears to be the first to address the association 
between NCQA HEDIS measures and diabetes complications in a commercially insured 
population.  While the study is limited by its reliance on administrative claims data, this is the 
same type of information that health plans are required to use when reporting NCQA measures.  
Claims data do provide a method for observing real-world treatment patterns that are unavailable 
in data collected in clinical trials. Thus, this study demonstrates the potential value of using 
administrative claims data in epidemiologic research on diabetes.   
5.2 CONCLUSION  
Although there is evidence that disease management for patients with diabetes improves 
processes of care and glycemic control, there is no evidence that these strategies improve other 
intermediate outcomes such as blood pressure or lipid control (Kern, 2006; Knight et al., 2005; 
Norris et al., 2002).  This study sought to determine whether adhering to the three QOCM 
guidelines was associated with reducing the risk of complications associated with diabetes over a 
six-year observation period.  The overall health benefits of diabetics who received all three 
QOCM at baseline were noteworthy; they experienced reduced risk for HF, RD and any of the 
four complications compared to the group that received less than three QOCM.  The results 
suggest that receiving all three monitoring tests for diabetes (two A1C tests, one 
microalbuminuria and one lipid screening per year) is associated with a reduced risk for these 
complications.  Although monitoring intensification can be constrained by patient and provider 
reluctance (in part because of the associated costs), these results suggest that any improvement in 
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screening is likely to reduce the risk of diabetes complications, revealing many implications for 
policy and health plan leaders.   
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